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Abstract 
 
Chronic Myeloid Leukemia (CML) is a hematological malignancy, characterized by 
the Philadelphia chromosome, resulting from the t(9;22)(q34;q11.2) translocation, which 
generates the BCR-ABL fusion gene. This genetic alteration originates a constitutively 
active tyrosine kinase, deregulating multiple downstream pathways and, thus, promoting 
cellular survival and proliferation. The gold standard treatment of BCR-ABL+ CML is the use 
of BCR-ABL inhibitors. Imatinib mesylate (STI571, Gleevec) is one of the most widely used 
drugs as first line treatment in the clinical practice. Unfortunately, even though these drugs 
are very effective for disease management, resistance to these molecules often arises 
(mostly due to mutations on the catalytic BCR-ABL domain, which is the target of these 
drugs), representing a major clinical drawback in the treatment of these patients. Recent 
studies have indicated that drug resistance may be horizontally transferred by extracellular 
vesicles (EVs), such as microvesicles and exosomes, from donor to recipient cells. 
Interestingly, is it known that EVs released by donor drug-resistant cells contain information 
that reflects the cells of origin, such as proteins, mRNAs or microRNAs.  
The main objectives of this work were to ascertain if: i) EVs released by BCR-ABL+ 
leukemia cell lines had BCR-ABL (protein and mRNA) on their cargo; and ii) EVs shed by 
a drug-resistant BCR-ABL+ cell line (KBM5-STI, with mutant BCR-ABL in T315I, which 
confers resistance to STI571) were responsible for intercellular transfer of a drug-resistance 
phenotype to their drug-sensitive counterpart cells (KBM5). 
To address this, the dose-response curves to STI571 of the above-mentioned pair 
of counterpart drug resistant and drug sensitive BCR-ABL+ cell lines were first performed, 
using the resazurin assay. EVs were then isolated from those cells using the 
ultracentrifugation protocol and were characterized by Dynamic Light Scattering (DLS), 
Nanoparticle Tracking Analysis (NTA), Transmission Electron Microscopy (TEM) and 
Western Blot (WB). The cargo of the EVs regarding BCR-ABL content was assessed by 
WB (and also preliminary assessed by quantitative Real Time-Polymerase Chain Reaction 
– qRT-PCR – which was performed by collaborators of the research team). Finally, the 
response of drug-sensitive cells to STI571 following co-culture with EVs shed by drug-
resistant cells was verified with the resazurin assay. 
The distinct growth of the two cell lines studied regarding their response to STI571 
was confirmed, being the IC50 of the drug resistant cell line about 100 times higher than 
the IC50 of the sensitive one. EVs characterization proved their successful isolation: the 
size distribution was the expected for these particles (10 – 1000 nm); their morphology was 
xx 
 
observed by TEM; and they presented several classical markers, with no evidence of 
cellular contaminants. Interestingly, BCR-ABL oncoprotein was detected in EVs released 
by both cell lines, with a stronger detection signal (on Western Blots) than the one found in 
the cells, for the same amount of protein analyzed. Thus, these results suggest that there 
might be a selective packaging of BCR-ABL into EVs, promoting a mechanism for 
oncoprotein shedding. Preliminary results obtained in collaboration with other researchers 
also showed the presence of BCR-ABL mRNA in those EVs. Nevertheless, under the 
conditions tested, the EVs released by KBM5-STI (resistant) cells did not influence the 
response of drug-sensitive recipient cells to STI571. In summary, under the conditions 
tested, the work presented in this thesis found no evidence for a transfer of drug resistance, 
mediated by EVs, from resistant to sensitive cells.  
 
Keywords: 
Chronic Myeloid Leukemia | BCR-ABL | Imatinib mesylate or STI571 | Drug resistance | 
Extracellular Vesicles | Horizontal transfer of drug resistance 
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Resumo 
 
A leucemia mieloide crónica (LMC) é uma doença maligna hematológica, 
caracterizada pelo cromossoma de Filadélfia, resultante da translocação t(9; 22)(q34; 
q11.2), que origina o gene de fusão BCR-ABL. Esta alteração genética dá origem a uma 
tirosina cinase constitutivamente ativa, desregulando múltiplas vias a jusante, 
promovendo assim a sobrevivência e proliferação celulares. O tratamento padrão da 
LMC BCR-ABL+ baseia-se no uso de inibidores de BCR-ABL. O imatinib mesylate 
(STI571, Gleevec) é um dos fármacos mais amplamente utilizados como tratamento de 
primeira linha na prática clínica. Infelizmente, apesar da eficácia destes fármacos no 
controlo da doença, surgem frequentemente casos de resistência a estas moléculas 
(principalmente devido a mutações no domínio catalítico do BCR-ABL, sendo esse o 
alvo destes fármacos), representando a maior desvantagem clínica no tratamento 
destes pacientes. Estudos recentes indicaram que a resistência a fármacos pode ser 
transferida horizontalmente por vesículas extracelulares (EVs), tais como 
microvesículas e exossomas, de células dadoras para células recetoras. Curiosamente, 
sabe-se que as EVs libertadas por células dadoras resistentes a fármacos contêm 
informação que reflete as células de origem, como proteínas, mRNAs ou microRNAs. 
Os principais objetivos deste trabalho foram verificar se: i) as EVs libertadas por 
linhas celulares leucémicas BCR-ABL+ continham BCR-ABL (proteína e mRNA) no seu 
interior; e ii) as EVs libertadas por uma linha celular BCR-ABL+ resistente ao fármaco 
(KBM5-STI, com BCR-ABL contendo a mutação T315I, que confere resistência ao 
STI571) seriam responsáveis pela transferência intercelular do fenótipo de resistência 
ao fármaco, para as correspondentes células sensíveis (KBM5). 
Para tal, curvas dose-resposta ao STI571 do supra-mencionado par de linhas 
celulares BCR-ABL+, sensível e resistente ao fármaco, foram inicialmente determinadas 
usando o ensaio da resazurina. De seguida, as EVs foram isoladas destas células 
usando o protocolo de ultracentrifugação e foram caracterizadas por diferentes 
métodos: Dynamic Light Scattering (DLS), Nanoparticle Tracking Analysis (NTA), 
Microscopia Eletrónica de Transmissão (TEM) e Western Blot (WB). O conteúdo das 
EVs relativamente à presença de BCR-ABL foi avaliado por WB (e também avaliado 
preliminarmente por Real Time-Polymerase Chain Reaction quantitativo – qRT-PCR – 
realizado por colaboradores do grupo de investigação). Finalmente, a resposta das 
células sensíveis ao STI571 após co-cultura com EVs libertadas pelas células 
resistentes ao fármaco foi verificada, usando o ensaio da resazurina. 
 
 
O crescimento distinto das duas linhas celulares estudadas relativamente à sua 
resposta ao STI571 foi confirmado, sendo o IC50 da linha celular resistente cerca de 
100 vezes maior do que o IC50 da sensível. A caracterização das EVs provou o sucesso 
do seu isolamento: a distribuição de tamanhos foi a esperada para estas partículas (10 
- 1000 nm); a sua morfologia foi observada por TEM; e apresentaram vários marcadores 
clássicos de EVs, sem evidências de contaminantes celulares. Curiosamente, a 
oncoproteína BCR-ABL foi detetada nas EVs libertadas por ambas as linhas celulares, 
com um sinal de deteção mais forte (nos Western Blots) quando comparado com o 
encontrado nas células, para a mesma quantidade de proteína analisada. Assim, estes 
resultados sugerem que poderá haver um empacotamento seletivo de BCR-ABL nas 
EVs, promovendo um mecanismo de libertação da oncoproteína. Os resultados 
preliminares obtidos em colaboração com outros investigadores também demonstraram 
a presença de mRNA de BCR-ABL nas EVs. No entanto, nas condições testadas, as 
EVs libertadas pelas células KBM5-STI (resistentes) não influenciaram a resposta ao 
STI571 das células recetoras sensíveis ao fármaco. Em suma, nas condições testadas, 
o trabalho apresentado nesta tese não encontrou evidências de transferência de 
resistência a fármacos, mediada por EVs, de células resistentes para células sensíveis. 
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Leucemia Mieloide Crónica | BCR-ABL | Imatinib mesylate ou STI571 | Resistência a 
fármacos | Vesículas Extracelulares | Transferência horizontal de resistência a fármacos 
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1.1. Cancer – a general overview  
 
In the last decades, cancer has become an emergent and serious public health 
problem worldwide [1]. According to data from the World Health Organization, an increase 
to 17.1 million new cases of cancer is predicted in 2020 (against 14.1 million cases in 2012). 
The numbers regarding mortality are also worrisome: 10.0 million deaths due to cancer are 
estimated for 2020 [2, 3]. Therefore, research on cancer is of great importance in order to 
reduce such devastating impact. 
Cancer is a heterogenous and multifactorial disease, about which much has been 
studied; however, despite growing research in the area and promising advances, much 
remains to be unveiled [4]. The rise in the incidence of cancer, in developed countries, is 
mostly due to ageing and lifestyle habits (such as smoking, consumption of alcohol, obesity 
and sedentarism), which represent risk factors for this disease. The substantial increase in 
the number of cancer cases in recent years is also related with the improvement of 
diagnostic methods. However, an early detection of this disease has an important impact 
on treatment success and survival of patients [4, 5]. 
The interaction between environmental and genetic factors is important for cancer 
development. Carcinogenesis is a slow and complex process, during which there is 
progressive accumulation of genetic and epigenetic alterations in cells, contributing to a 
malignant phenotype [6]. Major modifications derive from the occurrence of mutations in 
oncogenes and tumor suppressor genes in normal cells, triggering an uncontrolled cell 
growth by their activation (oncogenes) and/or inactivation (tumor suppressor genes), 
causing deregulation of several crucial pathways [7]. The carcinogenesis process is divided 
in some main steps: transformation (consisting of initiation and promotion), growth and 
progression (characterized by local invasion followed by metastization). In the first step, a 
cell must suffer genomic alterations caused by carcinogenic agents (chemical, physical or 
biological). A sequence of multiple alterations modifies key processes in the cell, such as 
proliferation and apoptosis, conferring a neoplastic phenotype to the cell, which provides 
selective advantage [7-9]. During cancer development, associated with genomic instability 
and an incorrect DNA repair, cells acquire autonomous and limitless growth capacity, 
insensibility to apoptotic and growth inhibitory signals and capacity of evasion from the 
immune system. Additionally, an inflammatory environment is promoted and the cellular 
energy metabolism is reprogrammed. All these factors, together with induction of 
angiogenesis and activation of invasion and metastasis, culminate in cancer progression 
and systemic dissemination of the cancer to other organs [8, 9].  
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Concomitantly with the malignancy of the tumor cells, the microenvironment in which 
cancer cells are involved also has a pivotal role in the pathophysiology of a tumor. Recently, 
the components of the milieu surrounding cancer cells have been studied, revealing their 
importance in the maintenance and expansion of the tumor, as well as in drug resistance 
(Figure 1) [10-12]. The relevance of the tumor microenvironment has recently been 
accepted and contrasts with the older studies that only focused on the biology of cancer 
cells without taking into account their surroundings [12]. In fact, endothelial cells, pericytes, 
cancer associated fibroblasts (CAFs), bone marrow progenitor cells, macrophages and 
cancer stem cells continuously interact with neoplastic cells, by sending external signals to 
each other. These cells, in association with the extracellular matrix and soluble secretion 
factors (e.g. growth factors) constitute the tumor microenvironment [13, 14]. Evidence 
suggest that targeting components of the tumor microenvironment could be a complement 
approach to current treatments, improving clinical outcomes and providing an extra level in 
therapeutic intervention [12, 15]. 
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Figure 1. Importance of the tumor microenvironment during tumorigenesis. HSC – 
Hematopoietic Stem Cells; MSC – Mesenchymal Stem Cells; LSC – Leukemia Stem Cells; EMT – 
Epithelial-mesenchymal Transition; TAM – Tumor-associated Macrophages; CAF – Cancer-
associated Fibroblasts; EC – Endothelial Cell; ECM – Extracellular Matrix; TC – Tumor Cell (adapted 
from  [12]). 
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1.2. Chronic Myeloid Leukemia (CML) 
 
1.2.1. Definition, molecular events and epidemiology  
 
Chronic myeloid leukemia (CML) is a hematological disease disturbing the myeloid 
(mostly granulocytic) compartment of the hematopoietic stem cell system. In 90 – 95% of 
the cases, this myeloproliferative disorder occurs from a reciprocal translocation between 
the BCR (Breakpoint Cluster Region) and ABL (Abelson) genes, on chromosomes 22 and 
9, respectively. Such chromosomal aberration, t(9;22)(q34; q11), originates the 
Philadelphia chromosome (Ph), which in turn generates the BCR-ABL oncoprotein [16-20]. 
This protein is a tyrosine kinase that leads to several alterations in critical mechanisms of 
the cell, by deregulation of important downstream pathways. Indeed, BCR-ABL acts on 
various substrates, such as the nuclear factor kappa B (NF-kB), Ras, mitogen activated 
protein kinase (MAPK), signal transducers and activators of transcription (STAT), c-jun N-
terminal kinase (JNK), phosphoinositide 3- (PI-3) kinase, stress-activated protein kinase 
(SAPK), and c-Myc. Hence, the constitutive activation of BCR-ABL drives changes in 
different cellular processes such as cell growth, differentiation, adhesion and apoptosis. The 
stimulation of these pathways leads to an independent proliferation associated with 
increased resistance to apoptosis (Figure 2) [21-26].  
Figure 2. Cascade of some downstream signal-transduction pathways affected by BCR-ABL. 
The deregulation of these pathways, by the constitutively activation of the BCR-ABL oncoprotein, 
alters crucial mechanisms in the cell, culminating in chronic myeloid leukemia. P indicates phosphate 
(adapted from [21]). 
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The worldwide incidence of CML is of 0.6 to 2.0 cases per 100 000 individuals. Thus, 
CML is a relatively rare pathology and it is most common in men. At diagnosis, the median 
age is 57 to 60 years (data from European CML registries), but it may be diagnosed in all 
age groups, even though with low frequency in young people [27, 28]. There is no 
association of this disease with race or ethnicity, nor with geographic or genetic 
predisposition; however, it is thought that ionization radiation in high doses is associated 
with CML. Among all leukemia cases, about 15% of them are of CML. Despite scarce 
reliable data from poor countries, it is estimated that 100 000 patients will be affected every 
year by CML globally, representing a significant worldwide health burden [28, 29].  
CML malignancy develops in three stages: chronic phase, accelerated phase and 
blast crisis. The first phase, in which 90% of the patients are diagnosed, is characterized by 
the excess of myeloid cells that retain the capacity to differentiate and to have normal 
function. Patients may remain approximately 3 to 8 years in this phase. When the disease 
progresses to the next phase, a gradual loss of differentiation and an accumulation of blasts 
occur. Lastly, the natural course of the disease culminates in the blast crisis, characterized 
by the presence of 20% or more blasts in the bloodstream or bone marrow, or by infiltration 
of blasts extramedullary or in the bone marrow compartment. This phase has an acute 
leukemia behavior, fast progression and extremely short survival (reduced to few months). 
The accumulation of molecular anomalies may drive the increasing loss of the ability of 
leukemic cells to differentiate [18, 30]. Of note, normal and leukemic hematopoiesis have a 
common origin, since progenitor cells may undergo transforming mutations becoming a 
tumorigenic progenitor cell (Figure 3). 
The clinical presentations are frequently granulocytosis (higher amount of 
leukocytes, mainly granulocytes, in the blood), hypercellularity of the bone marrow and 
splenomegaly. Nevertheless, approximately 40% of patients do not have symptoms and 
CML is often diagnosed based on abnormal blood cell counts, found in a blood test 
performed with another purpose [16]. When CML is detected, symptoms are often mild at 
the beginning and become slowly more aggressive. Some of the symptoms are: tiredness, 
fever, sweating excessively, weight loss, early satiety, itching, bleeding, bone pain and 
abdominal swelling or discomfort caused by an enlarged spleen. Agents such as 
hydroxyurea and interferon-α (IFNα) can be used to control the symptoms, even though 
they are not able to cure the patients. The blast crisis is non-responsive to therapies and 
culminates irrevocably in death [31].   
 The usual procedures used to diagnose CML are: physical exam (pulse and blood 
pressure check, lymph nodes and examination of abdominal abnormalities); blood tests 
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(complete blood count); bone marrow tests (collection of bone marrow from hipbone, by 
biopsy or aspiration); tests for searching the Ph chromosome or the BCR-ABL gene 
(analysis of blood or bone marrow samples by specific tests, such as polymerase chain 
reaction – PCR, and fluorescence in situ hybridization – FISH) [32]. 
 
 
 
Figure 3. Schematization of the normal and leukemic hematopoietic hierarchies. A small 
population of self-renewing cells, the hematopoietic stem cells (HSC), sustains and originates 
lineage-restricted cells, with progressively differentiation and reduced self-renewal ability, producing 
mature blood cells. By the acquisition of mutagenic events, leukemic stem cells (LSC) may arise 
either from HSC, multipotent progenitors (MPP) or committed progenitor cells [33] (however, this 
topic remains controversial since some authors defend that only HSC could give origin LSC [34]). 
LSC share some features with normal HSC, driving CML progression, but having an altered 
differentiation program, as shown by the aberrant expression of several cell-surface markers 
(indicated in blue) and by the expression of the oncogene BCR-ABL. (Adapted from [33] and from 
[35]) 
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1.2.2. Targeted drugs to treat CML 
 
 
Prior to the use of BCR-ABL targeted therapies, some other options had been used 
in the management of CML. In the beginning of 20th century, an arsenic solution was the 
first treatment for CML. Other treatment options then followed such as: spleen irradiation 
and the use of busulfan, hydroxyurea and cytosine arabinoside (cytarabine). Nonetheless, 
they presented high toxicity and, in some cases, although they provided improvements in 
terms of decreased symptoms, it did not prolong patients’ lives [36, 37]. 
Interferon-α (IFNα), a nonspecific immunostimulant, was the first drug found to have 
the capacity of extending the first stage of the disease and delaying the progression to the 
accelerated phase. IFNα acts by regulating T-cell activity and provides encouraging 
responses, namely complete hematologic response (CHR) and complete cytogenetic 
response (CCyR) – which definition is clarified in the next section – thereby prolonging the 
median survival. Nevertheless, due to the lack of specificity, toxicities arose and secondary 
symptoms appeared, leading to the discontinuation of this therapy [38, 39]. 
Allogeneic stem cell transplantation provides long-term outcomes, being the only 
curative therapy proven so far. Still, it has been associated with high morbidity and mortality, 
and it is difficult to find available matched donors. Moreover, it is known that quiescent CML 
stem cells persist after transplantation, highlighting the need to find effective alternatives 
[40-43].  
 
1.2.2.1. Imatinib mesylate (STI571) 
 
The BCR-ABL tyrosine kinase activity is a key factor for CML pathophysiology [44]. 
Once identified, this molecule became a potential target for developing a selective inhibitor. 
Lydon and colleagues designed, in 1996, various compounds which inhibit the BCR-ABL 
domain. Among all compounds tested, they found the 2-phenylaminopyrimidine, which gave 
rise to imatinib mesylate (also called STI571, CGP57148B or Gleevec®, from Novartis 
Pharmaceuticals) [45-47]. 
STI571 (Figure 4) was highly effective in targeting cells expressing BCR-ABL 
protein. The drug was also selective for platelet-derived growth factor receptor (PDGF-R) 
and for the c-kit receptor. STI571 was first used in phase I clinical trials in 1998, 38 years 
after the first description of the Ph chromosome. Due to the undoubtedly satisfactory results, 
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it continued to phase II and III clinical trials, being approved in 2001 by the Food and Drug 
Administration (FDA) [46-52].  
 
 
 
 
 
Figure 4. Imatinib’s molecular structure. 
 
The tyrosine kinase inhibitor (TKI) STI571 binds to the catalytic pocket of the BCR-
ABL protein tyrosine kinase, competing with ATP for this site. In this way, the 
autophosphorylation of BCR-ABL and the phosphorylation of its substrates is inhibited, 
preventing the activation of other effector molecules [25, 44, 47, 53, 54].   
The standard regimen of STI571 doses consists of 400 mg daily (adults) or 260-340 
mg/m2/day (children) [55]. STI571 is highly effective and better tolerated than the previous 
therapies, having strongly improved the quality of life of these patients. However, in some 
cases, patients have a refractory disease, relapse or are intolerant to STI571, leading to 
treatment discontinuation[23]. Therefore, it was necessary to develop second generation 
TKIs that could overcome STI571 resistance [56-58].  
Nilotinib (Tasigna®, from Novartis Pharmaceutical) and Dasatinib (Sprycel®, from 
Bristol-Myers Squibb) were developed to treat patients who did not response to first line 
treatment with STI571. These drugs are much more potent against BCR-ABL than STI571 
and about 50% of patients who previously showed resistance to STI571 will reach a 
complete cytogenetic remission. Nonetheless, these drugs are not effective against the 
most common mutations in the BCR-ABL domain, particularly the T315I mutation, known 
to cause resistance to these drugs [59-62]. Hence, various other TKIs have been found to 
overcome new cases of resistance, such as Bosutinib (Bosulif®, from Wyeth) and Ponatinib 
(Iclusig®, from ARIAD Pharmaceuticals). This last drug is able to inhibit the most common 
type of mutation in BCR-ABL which is responsible for most cases of drug resistance, the 
T315I mutation [63-65].  
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1.2.3. Resistance to BCR-ABL tyrosine kinase inhibitors (TKIs) 
 
Development of various drugs targeting BCR-ABL, known to have a central role in 
CML pathogenesis, represented a huge improvement in CML patients’ clinical outcomes. 
Nonetheless, even though TKIs were effective in approximately 80% of CML cases, it was 
found that 20% of the patients do not respond to the first generation drugs[66].  
First, it is important to understand how therapeutic response is monitored in CML. 
In a simplified way, the criteria established for successful response to therapy include: 
• Complete Hematologic Remission (CHR): characterized by normal blood cell count and 
total disappearance of symptoms of the disease; 
• Complete Cytogenetic Response (CCyR): meaning the total absence of Ph+ 
metaphases (in a total of 20 bone marrow metaphases analyzed); 
• Complete molecular response (CMR), with no detection of BCR-ABL transcripts (this 
however depends on the sensitivity of the test, therefore there is no globally accepted 
definition for CMR) [67].  
 
According to this, definition of resistance to STI571 consists of incapacity to 
accomplish any of the criteria: CHR at 3 months, any CyR at 6 months, partial CyR at 12 
months or CCyR at 18 months of STI571-treatment [68].  
Cancer drug resistance may be intrinsic, caused by preexisting mechanisms, 
whereby malignant cells are resistant to therapies even before treatment initiation [69, 70]. 
This is also known as primary resistance and it is the cause of < 10% of TKIs resistance 
cases, occurring during chronic phase [71]. Alternatively, drug resistance can be acquired 
during treatment, due to mechanisms acquired during the “selective pressure” caused by 
the drug [69, 70]. This acquired resistance is also called secondary resistance and it is drug 
induced, occurring mostly in CML late stages [71-73]. The molecular procedures behind this 
resistance are divided into BCR-ABL-dependent and independent mechanisms [26, 74].  
A deep understanding of the molecular mechanisms responsible for drug resistance 
of CML patients is essential in order to implement the most adequate therapies and search 
for novel and alternative drugs.  
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1.2.3.1. BCR-ABL-dependent mechanisms  
 
1.2.3.1.1. BCR-ABL mutations  
 
The occurrence of point mutations in the BCR-ABL kinase domain is the most 
common mechanism responsible for TKIs resistance. These mutations, occurring in 
residues that direct bind to STI571, generate conformational alterations of BCR-ABL 
therefore decreasing the affinity of TKIs to the BCR-ABL domain [56, 75].  
More than 100 mutations were identified until now, varying in clinical relevance [75]. 
The T315I (Th315→Ile315) mutation was the first reported point mutation that confers 
resistance to TKIs and is the most common among cases of patients with resistance. The 
genetic region affected codes for the ATP-binding site of the ABL domain and results in a 
substitution of a threonine (Thr) by an isoleucine (lle) at amino acid 315. This “gatekeeper” 
mutation prevents the hydrogen bond to be formed between the oxygen of the side chain 
of threonine 315 and the NH2 group of STI571. Indeed, isoleucine has a hydrocarbon extra 
group, inhibiting STI571 binding [76]. The T315I mutation confers resistance to all BCR-
ABL inhibitors approved so far, except to Ponatinib [65].  
There are other relevant mutations which cause TKIs’ resistance, mapped in 
different sites of the kinase domain. The other most common mutations are the E255K 
(located in the P-loop) and the H396P (located in the activation loop), which are conserved 
and flexible loops, respectively. The P-loop (phosphate- or ATP-binding loop) forms the top 
of the active site of BCR-ABL and is responsible for coordinating the phosphate group of 
the ATP molecule (Figure 5). The activation loop acts as a backbone of the binding 
substrate, so it can be phosphorylated. By destabilizing the desired conformation for binding 
to STI571 and other BCR-ABL inhibitors, these mutations represent an important 
mechanism of drug resistance, associated with bad prognosis [47, 77-79].  
Evidence suggests that it is not the drug treatment that induces such mutations. 
Instead, it is believed that these mutations are already present within some of the tumor 
cells (due to tumor heterogeneity) conferring advantage to those cells when under the 
presence of the drug, by selective selection. In other words, these rare mutant clones pre-
exist in the tumor and have the ability to survive and proliferate even under treatment with 
these drugs, gradually taking over the drug-sensitive cells [80]. 
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Figure 5. Ribbon illustration of ABL complexed with Imatinib. Imatinib (STI, in orange) occupies 
the ATP-binding site (P-loop) of ABL protein (blue) when the A-loop is in the closed configuration. 
The relative positions of three of the most frequently mutated residues are also represented: 1 – 
T315I, in the gateway position; 2 – E255K, in the P-loop; and 3 – H396P, in the activation loop 
(adapted from [44]) 
 
1.2.3.1.2. BCR-ABL amplification  
 
The amplification of the BCR-ABL fusion gene and, consequently, the 
overexpression of the BCR-ABL oncoprotein may also provide relative resistance to TKIs. 
The resistance occurs because of the higher quantity of the target protein which is needed 
to be blocked by a therapeutically acceptable dose [81, 82]. This mechanism of resistance 
represents about 18% of the cases of STI571 treatment failure (against approximately 50% 
of resistance cases due to point mutations, referred above). It was shown that the 
amplification of the gene decrease after discontinuation of the treatment for some weeks, 
suggesting that continuous STI571 administration may cause a selection of cells with 
increased copies of BCR-ABL [76].   
 
Nevertheless, a considerable proportion of cases of TKIs resistance is not caused 
by BCR-ABL overexpression, neither by point mutations in the kinase domain (indeed, 
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some of the mutations detected do not cause loss of sensitivity to STI571). Thereby, drug 
resistance might be caused by other mechanisms, non-dependent of BCR-ABL [74].  
 
1.2.3.2. BCR-ABL-independent mechanisms 
 
1.2.3.2.1. Overexpression of drug-efflux proteins   
 
ATP-binding cassette – ABC – transporters are a superfamily of transmembrane 
proteins that were found to cause the efflux substrate drugs from the cell, leading to a 
decrease on the drugs intracellular concentrations, thus promoting chemoresistance [69, 
83]. Multidrug resistance (MDR) is a phenomenon corresponding to the development of 
concomitant resistance to various drugs, independently of their mechanism of action or 
chemical structures. MDR is frequently associated with overexpression of these ATP-
dependent pumps [84].  
Some BCR-ABL+ cell lines resistant to STI571 and CML stem cells were described 
to overexpressed ABC proteins, such as P-glycoprotein (P-gp, ABCB1 or MDR1) and the 
ATP-binding cassette sub-family G member 2 (ABCG2 or BCRP). Of note, STI571 is a 
substrate for these proteins. So, it is accepted that drug-efflux pumps are responsible for 
some cases of STI571 resistance, by decreasing the bioavailability of the drug inside of the 
cell [85-91].  
 
1.2.3.2.2. Activation of alternative signaling pathways 
 
The cellular dependence on the original drug target (BCR-ABL) can be alleviated by 
the permanently activation of BCR-ABL downstream signaling pathways, such as the 
kinases of the Src family. These kinases keep working even in the presence of STI571, 
suggesting that they might contribute to a BCR-ABL-independent mechanism of resistance. 
On the other hand, the Src family of kinases may phosphorylate the SH2 and SH3 (Src-
homology-2 and -3) domains of BCR-ABL, leading to an increase in the BCR-ABL kinase 
activity and therefore altering the cellular susceptibility to STI571. Several pathways of 
intracellular signal transduction are modulated by the Src family, such as those involved in 
survival, cell growth and tumor dissemination. Therefore, therapies based on anti-Src family 
of kinases, simultaneously targeting BCR-ABL, could be a powerful tool to overcome some 
cases of drug resistance. In fact, the combination of dual inhibitors (e.g. dasatinib and 
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bosutinib) suggested that it was possible to counteract cases of STI571 resistance, except 
for the cases due to T315I BCR-ABL mutant [54, 74, 92]. 
The p53 pathway also has an important role in response to STI571 therapy. p53 
inactivation (often associated with CML progression) blocks, both in vitro and in vivo, cellular 
response to this drug. Therefore, mutations that affect the p53 pathway may contribute to 
STI571 resistance in later phases of CML [93].  
Moreover, autocrine loops might also contribute to resistance to STI571. Indeed, 
interleukin-3 and granulocyte-colony stimulating factor (G-CSF) were produced by CD34+ 
primitive cells in patients in the chronic phase of the disease. Such cytokines promote the 
autocrine stimulation of cellular proliferation events (by pathways such as JAK/STAT and 
Ras/Raf/Mek pathways), therefore preventing STI571-induced apoptosis [94].  
 
Besides, other mechanisms have been further reported, with relevant contribution 
to drug resistance and consequently to treatment failure. For instance, the presence of a 
quiescent population of primitive BCR-ABL+ stem cells is a major cause responsible for 
relapses. This population of stem cells is preserved in bone marrow niches and, when 
treatment with TKIs is discontinued, they may spontaneously leave the G0 phase and 
acquire a state of constitutive proliferation [94-96]. In addition, point mutations outside the 
BCR-ABL kinase domain have also been described in cases of drug resistance, often in 
positions essential for the maintenance of the inactive state of the oncoprotein (such as in 
N-terminal region and the SH2 and SH3 domains) [56]. Finally, the under-expression of 
drug uptake transporters, such as the human organic cation transporter 1 (hOCT1), may 
also decrease the intracellular STI571 concentration [97, 98]. 
Therefore, BCR-ABL-independent mechanisms have a great impact in CML 
progression.  
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Figure 6. Summary of several mechanisms of resistance against tyrosine kinase inhibitors.  
BCR-ABL-dependent and -independent mechanisms are depicted in green and blue, respectively. 
(Adapted from [26]) 
 
 
 
1.3. Transfer of drug resistant traits by Extracellular Vesicles (EVs) 
 
1.3.1. Exosomes and microvesicles: biogenesis, release by donor cells and uptake 
by recipient cells 
 
The complex interactions occurring in the tumor microenvironment are maintained 
by a constant influx and efflux of biological material through the cellular membrane. In 
addition to active and passive transport, there are other mechanisms through which cells 
communicate with the outside environment (with the microenvironment of the cells or with 
distant sites). Intra- and intercellular communication between neoplastic and non-neoplastic 
cells is achieved by cell-cell interactions (gap junction-mediated), paracrine mechanisms 
(growth factors, chemokines and proteases) as well as by extracellular vesicles (EVs). It is 
believed that communication mediated by EVs provides a mechanism by which more 
complex information can be exchanged between cells [99-104].   
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EVs are small structures but variable in size (10 – 1000 nm), surrounded by a lipid 
bilayer and produced by all types of cells, prokaryotic and eukaryotic, under physiological 
or pathological conditions. They have been isolated from several biological fluids such as 
blood, semen, breast milk, urine, saliva, bile, amniotic fluid and cerebrospinal fluid. These 
nanoparticles are important mediators of intercellular communication. EVs are mainly 
exosomes, microvesicles and apoptotic bodies. The exosomes are the smallest, with a size 
range between 30 – 100 nm and with an endosomal origin. They are formed within 
endosomes, which are known to pass through different stages. The late endosomes, known 
as multivesicular bodies, culminate in lysosome fusion (with destruction of their content) or 
fusion with the plasmatic membrane followed by release of exosomes from the cell. On the 
other hand, the microvesicles are larger in relation to exosomes (50 – 1000 nm) and are 
generated by direct budding of the plasma membrane, resulting from a dynamic interchange 
between contraction of cytoskeletal proteins and redistribution of phospholipids. Finally, 
apoptotic bodies are the largest vesicles (from 500 to 4000 nm) and are released during 
apoptosis due to membrane blebbing [105-108].   
Efforts have been done in order to discover proteins present in EVs that allow 
distinguishing between microvesicles and exosomes. It was found that exosomes contain 
heat-shock proteins (HSP70 and HSP90), tetraspanins (including CD9, CD63 and CD81) 
and proteins involved in immunologic functions, like molecules of the major 
histocompatibility complex class II. Nevertheless, recent research showed that these 
proteins are also present in cell pellets enriched with larger EVs. Therefore, it is difficult to 
find reliable specific markers of exosomes versus microvesicles. Indeed, this is a relatively 
recent field of research and standardization of nomenclature and protocols need to be 
optimized [106, 109, 110]. 
Regarding their release and uptake mechanisms, it is believed that EVs shed by 
donor cells might interact only with recipient cells that they specifically recognize. However, 
further work needs to be done to fully understand this phenomenon. The uptake of EVs by 
recipient cells may occur either by: i) docking at the plasma membrane of the recipient cell, 
ii) direct fusing with the plasma membrane of that cell (thereby delivering the cargo of the 
EVs into the membrane or the cytosol of the recipient cell), or iii) by endocytosis (thus fusing 
the EVs with an endocytic organelle) [100, 105, 106].  
EVs released by tumor cells contain biological material from the donor cells. The 
transfer of their cargo to recipient cells may contribute to tumor growth and metastasis [111-
116].  
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The EVs cargo may include microRNAs (miRNAs), mRNAs or other types of RNA 
(such long noncoding RNAs lncRNAs), proteins (mainly the ones involved in vesicles 
formation, but also others such as oncoproteins or drug efflux pumps), lipids (such as 
phospholipids, glycerophospholipids, sphingolipids) and even small pieces of genomic DNA 
[117, 118].  
Some studies have suggested that cancer cells produce more EVs than normal 
cells. Furthermore, it has been demonstrated that the quantity of shed vesicles changes 
during cancer development and their cargoes are different in tumors with high or low 
metastatic potential [119-121].  
Emerging evidence supports the possibility that EVs might become a good source 
of biomarkers of disease, considering their content in specific molecules from the donor cell, 
thus reflecting the cell of origin [101, 122-124].  
Interestingly, alternative therapies based on EVs have been proposed. Therapies 
proposed so far include activation of the immune system by dendritic cell-derived exosome-
based vaccines; the use of EVs for transport and delivery of drugs, miRNAs or siRNAs to 
targeted cells; and the selective removal of EVs released by cancer cells, from the blood 
and other body fluids, by a process similar to hemodialysis [113, 125-128].  
 
1.3.2. Role of EVs in tumorigenesis and drug resistance 
 
EVs are important players on tumor development and resistance. For example, it is 
believed that EVs released by cancer cells or by various cells that compose the tumor 
microenvironment may influence tumor heterogeneity. Additionally, EVs may modulate the 
immune response (enabling immune evasion of the tumor cells and contributing to initiating 
the inflammatory response) or participate in the differentiation of CAFs (transporting growth 
factors, such as TGF-β1 and FGF-2) and transport the bioactive molecules produced by 
them (such as interleukin-6 and prostaglandins). In addition, EVs can trigger angiogenesis 
and help in the metastatic process, by inducing the epithelial to mesenchymal transition or 
by preparing the pre-metastatic niches. Moreover, EVs also take part in some cancer drug 
resistance (CDR) processes, being described as a remarkable vehicle of CDR 
dissemination [110-112, 116, 123, 126, 129, 130]. Indeed, EVs released from donor drug-
resistant cells may horizontally transfer mediators of CDR to recipient drug-sensitive cells. 
Afterwards, the recipient cells may acquire the drug-resistant phenotype by incorporating 
the cargo of such vesicles. The cargo of EVs which may mediate CDR spreading might 
include miRNAs, lncRNAs or drug-efflux pumps (Figure 7) [111, 117]. 
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The miRNAs may be encapsulated into EVs, conferring them high stability and 
protection from the action of RNases. In addition, miRs contained in EVs may function as 
signaling molecules that influence the targeted cells phenotype [131]. In 2012, Jaiswal R. 
and his collaborators analyzed, in hematological and non-hematological models, the miRNA 
profiles of drug-sensitive recipient cells, after co-culture with EVs derived from drug-
resistant cells. They found that there was a transfer of CDR traits into recipient cells, 
mediated by selective packaging of miRNAs into those EVs by the donor cells [132]. 
Although the role of lncRNAs in CDR is not clearly understood, studies have 
reported the enrichment of these RNAs in EVs, together with an increase in their expression 
in the donor cells after chemotherapy treatment. Besides, a study in which EVs derived from 
hepatocellular cancer cells, after treatment with several chemotherapeutic agents (with 
consequent enrichment in lincRNA-VLDR), were co-cultured with recipient cells, showed an 
upregulation of a lncRNA in the recipient cells and a reduction in apoptosis induced by 
chemotherapy [133, 134].   
The presence of drug efflux pumps in the cargo of EVs has also been found. As 
mentioned above, those proteins are involved in the efflux of drugs, thereby decreasing the 
concentration of substrate drugs to sublethal levels. It was shown that these pumps may be 
transferred by EVs to recipient cells, providing a mechanism of intracellular transfer of 
multidrug resistance [135, 136].  
Other type of molecules carried in EVs shed by drug-resistant cells may also 
mediate propagation of CDR traits, by inducing EVs production or regulate other mediators 
of drug resistance. An example is the mRNA encoding inhibitors of apoptosis proteins 
(IAPs), found to be present in EVs from CML cell lines. Incubation of drug-sensitive cells 
with EVs derived from drug-resistant cells promoted the accumulation of P-gp and miRNAs, 
as well as IAPs in recipient cells. The resistance then exhibited by the recipient cells was 
proposed to be a result of the transfer of all the three mediators.  
Interestingly, there is controversy regarding the possibility of selectivity for the 
recipient cells of EVs. Indeed, some recent studies indicated that EVs may have “tissue 
selectivity”. In one of those studies, breast cancer cells overexpressing P-glycoprotein (P-
gp) transferred this protein (via EVs) only to malignant recipient cells. However, the same 
study showed that leukemia cells released EVs that transferred P-gp and multidrug 
resistance-associated protein 1 (MRP-1), to both malignant and non-malignant cells [137]. 
In another study, CML cells exhibited no selectivity associated to the cell type of recipient 
cells, since EVs from drug-resistant CML cells transferred P-gp to drug-sensitive cells of 
both breast and lung cancer cells [138]. Taken together, such findings suggest that further 
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research is needed in order to understand if there is selectivity on the process of intercellular 
transfer of EVs cargo. 
In summary, the horizontal transfer of drug resistance mediated by EVs has recently 
been discovered as a relevant mechanism of propagation of a CDR phenotype. Indeed, it 
was shown that not only the mediators of drug resistance are transferred into recipient cells, 
through EVs shed by donor drug-resistant cells, but also that they are functional in the 
recipient cells [117]. 
  
  
 
 
 
 
Figure 7 Intercellular transfer of drug resistance mediated by extracellular vesicles. These 
vesicles are involved in intercellular communication, particularly the microvesicles (which emerge 
from direct budding of the plasma membrane of the cell) and exosomes (with endocytic origin, formed 
by inner sprouting of the multivesicular body, MVB, membrane). Drug resistance transfer may occur 
20 
 
from drug-resistant cells (donor of EVs) to drug-sensitive cells (recipient of EVs) mediated by 
extracellular vesicles (EVs). The cargo of the EVs may include, among other components, proteins 
(such as drug-efflux pumps), miRNAs and long noncoding RNAs (lncRNAs), responsible for cancer 
drug resistance dissemination. Once the recipient cell is reached, EVs may be internalized by 
endocytosis or may fuse with the cellular plasma membrane. Small green vesicles represent 
exosomes and bigger brown vesicles represent microvesicles. ESCRT – Endosomal Sorting 
Complex Required for Transport; Rabs – Ras-associated binding proteins; SNAREs – Soluble N-
ethylmaleimide-sensitive factor Activating protein Receptor; ER – endoplasmic reticulum; mRNA – 
messenger RNA; miRNA – micro RNA; MHC – major histocompatibility complex. (adapted from 
[117]) 
 
Many questions in this recent field of research still have no answer but it is expected 
that, in the near future, clinical data will elucidate the real impact of this type of CDR transfer 
in patients’ response to treatments and clinical outcome [117]. 
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1.4. Aims 
 
1.4.1. Main aim 
 
The overall aim of the present work is to investigate if: 
i) EVs released by BCR-ABL+ chronic myeloid leukemia cells had BCR-ABL on their 
cargo; and ii) EVs shed by a drug-resistant BCR-ABL+ cell line (KBM5-STI, harboring an 
additional point mutation in BCR-ABL, which confers resistance to STI571) were 
responsible for intercellular transfer of drug-resistance to their drug-sensitive counterpart 
cells (KBM5). 
 
1.4.2. Specific aims 
 
The specific aims of the present work were to: 
 
i. Characterize the pair of counterpart cell lines, KBM5 and KBM5-STI, 
regarding response to STI571 in order to confirm their drug sensitive and resistant 
phenotypes, respectively; 
ii. Isolate EVs from those cell lines and characterize them according to their 
size, morphology and protein content;  
iii. Investigate if EVs released by these BCR-ABL+ leukemia cell lines carry 
BCR-ABL (in terms of protein and mRNA) on their cargo; 
iv. Verify if drug resistance could be transferred from leukemic drug resistant 
cells (with mutant BCR-ABL) to leukemic drug sensitive cells (with wild-type BCR-ABL).   
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II. Materials  
and Methods  
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 2.1. Cell culture  
 
The human chronic myeloid leukemia (CML) cell lines, KBM5 (sensitive to imatinib) 
and its BCR-ABL mutated counterpart cell line KBM5-STI (resistant to imatinib and 
generated from the parental KBM5 cell line), were kindly provided by Dr. Miloslav Beran 
and Dr. Bing Z. Carter from the University of Texas M.D. Andersen Cancer Center, Houston, 
Texas [139, 140].  
KBM5 and KBM5-STI cell lines grow in suspension and were routinely grown in 
RPMI-1640 medium, with Ultraglutamine I and 25 mM HEPES (Lonza), supplemented with 
10% fetal bovine serum (FBS, from Biowest) at 37 ºC in a humidified atmosphere containing 
5% CO2. The KBM5-STI resistant cell line was maintained in culture in the presence of 1 
μM imatinib mesylate, STI571 (Gleevec®, from Sigma-Aldrich, Co.), by addition of the drug 
to the medium following each passage. Cells were frequently observed using an inverted 
light microscope and they were passaged every 2-3 days (when reaching about 90% 
confluency). For that, confluent cells were collected and centrifuged at 130 x g (Centrifuge 
5810R, Eppendorf) for 10 min, the supernatant discarded and the pellet resuspended in 
fresh medium and transferred into a new cell culture flask. 
The cell lines were genotyped and routinely monitored for mycoplasma 
contamination by using the Polymerase Chain Reaction, PCR (VenorGeM® Advance 
Mycoplasma Detection Kit, Minerva). These analyses were performed by the Service 
platforms of i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto 
(Cell Culture and Genotyping Service). 
All procedures involving cell culture were performed under extremely clean and 
sterile conditions, in biological laminar flow hoods. Aseptic technique was used for handling 
sterile reagents and materials. Cell number and viability were routinely analyzed with the 
trypan blue exclusion assay. All experiments were carried out when cells were in 
exponential growth and having over 90% viability. 
 
2.2. Cellular viability and proliferation assays  
 
2.2.1. Trypan blue exclusion assay  
 
The cell number was frequently counted using a hemocytometer (Neubauer 
Chamber) and the Trypan Blue reagent (Sigma-Aldrich, Co.), in order to maintain the cells 
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at an appropriate density (around 5 × 105 cells/mL) and to ascertain cell viability values 
(ideally over 90%). Trypan blue penetrates the membrane of disrupted cells, allowing to 
distinguish between alive and dead cells (blue ones).  
 
2.2.2. Resazurin assay 
 
The resazurin assay is based on the capacity of metabolically active cells to reduce 
the dye resazurin into resorufin – a pink fluorescent product that can be easily measured 
by fluorescence, using a 530 nm excitation and 590 nm emission filter set [141, 142]. Thus, 
resazurin is a cell permeable redox indicator that can be used to monitor viable cells. 
 
 
 
 
 
 
 
Figure 8. Resazurin reduction reaction from metabolically active cells. 
 
2.2.2.1. Dose-response curves of KBM5 and KBM5-STI cells to imatinib mesylate 
(STI571) 
 
Dose-response curves to imatinib (STI571) were performed, to confirm the 
respective sensitive and resistant phenotypes of the KBM5 and KBM5-STI cell lines and to 
determine the drug’s concentration which inhibits cell growth by 50% (IC50).  
To that end, 80 μL of cellular suspensions of both cell lines (in the optimal 
concentration previously determined by other members of the team – 1.5 x 105 cells/mL) 
were seeded in a 96-well plate. After 24 h, 10 μL of a range of different concentrations of 
STI571 were added to the cells. Ten different concentrations of STI571 were tested:  0.04 
μM, 0.08 μM, 0.15 μM, 0.31 μM, 0.63 μM, 1.3 μM, 2.5 μM, 5.0 μM, 10 μM and 20 μM. The 
higher concentration of STI571 (20 μM) was prepared from a stock of 10 mM (dissolved in 
DMSO, stored at -20 ºC and protected from light) and the following concentrations were 
prepared by successive dilutions. These concentrations were selected taking into account 
Resazurin 
NADH NAD
+ 
Resorufin 
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the IC50 values described in the literature [140]. After 48 h treatment with STI571, 10 μL of 
resazurin solution (1:9 proportion, Sigma-Aldrich, Co.) was added to each well, and the 
fluorescence was measured following 4 h incubation period at 37 ºC, protected from light. 
Fluorescence was then measured at both 530 nm and 590 nm (excitation and emission 
wavelengths, respectively) using a microplate reader (BioTek’s SynergyTM Mx) and the 
Gen5 software (BioTek). The IC50 (the concentration of STI571 that inhibits cell growth in 
50%) was then determined by interpolation from the obtained curves. The schematic 
representation of the plate is shown in Annex 1.  
Results were presented by the average plus or minus standard errors from at least 
3 independent experiments, generated by Excel. 
 
2.3. Extracellular Vesicles (EVs) isolation 
 
EVs were isolated from KBM5 and KBM5-STI cells using the ultracentrifugation 
method, as previously described [143]. Cells were cultured during 3 days in EV-depleted 
culture medium (medium containing FBS which had been ultracentrifuged at 100 000 x g 
overnight, at 4ºC and filtered with a 0.2 μM pore filter, in order to remove EVs from the 
serum). Then, EVs were isolated following a sequential centrifugation procedure, as 
summarized below (Figure 9). 
First, the cell suspension was centrifuged at 200 x g (centrifuge 5810R, Eppendorf) 
during 10 min to remove the cells. The succeeding supernatant centrifugation steps were 
carried out at 4 ºC in the same centrifuge: a centrifugation during 10 min at 300 x g to 
remove remaining cells and dead cells, followed by a centrifugation during 10 min at 2 000 
x g to remove cell debris and apoptotic bodies. Next, the supernatant was centrifuged using 
a High Speed Centrifuge (AVANTI J-25, Beckman Coulter), for 30 min at 10 000 x g to 
remove other large vesicles. Then, the supernatant obtained was ultracentrifuged (Optima 
XE-100 Ultracentrifuge, Beckman Coulter) during 70 min at 100 000 x g in order to pellet 
the intended EVs (mostly microvesicles and exosomes). The pellet was finally washed in 
PBS and again ultracentrifuged at 100 000 x g for 70 min to remove medium and secreted 
proteins [144]. The ultracentrifugation steps were carried out using the Type 70 Ti Rotor, 
Fixed Angle, with the 26.9 ml Quickseal tubes.  
In addition, after each centrifugation, the supernatants were carefully transferred into 
new tubes without disturbing the pellets, in order to avoid contamination. Tubes used in 
these centrifugations were prior washed with a proper detergent (DERQUIM LM 01 Alkaline 
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LIQUID, from PVL - Produtos para Laboratório, Lda), avoiding microbiologic contaminations 
and contaminations among samples and experiments. 
Whenever EVs were isolated to further co-culture experiments, all isolation 
procedures were performed under sterile conditions, using autoclaved tubes (20 min at 
121ºC) and performing inside of a laminar flow hood. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Simplified scheme of the process of EVs isolation by the differential 
ultracentrifugation method.  
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2.4. EVs characterization  
 
The EVs isolated by ultracentrifugation were then analyzed and characterized by 
size and protein content, using the methods described below. 
 
2.4.1. Dynamic Light Scattering (DLS) 
 
Dynamic Light Scattering (DLS) was performed to measure the size/diameter of the 
isolated EVs. The final pellet obtained by ultracentrifugation, which contain EVs, was 
dissolved in 70 μL of PBS and added to a polystyrene cuvette with 10 mm path length. DLS 
analysis was performed using the Zetasizer Nano ZS system and software (Malvern 
Instruments). The mean hydrodynamic diameter of the EVs was calculated by fitting a 
Gaussian function to the measured size distribution. Measurements were conducted at 
25ºC, operating at 633 nm and recording the back scattered light at a 173º angle. Samples’ 
temperature was allowed to equilibrate for 2 min before each measurement. Data obtained 
corresponds to a graph reflecting size distribution by number, allowing to infer the 
subpopulations of EVs which compose the sample.  
 
2.4.2. Nanoparticle Tracking Analysis (NTA) 
 
The Nanoparticle Tracking Analysis (NTA) technique also allows characterizing EVs 
regarding their size. Thus, the EVs pellet (after ultracentrifugation) was dissolved in 70 μL 
of PBS and then their protein content was quantified using a modified version of the Lowry 
assay (Bio-Rad DC Protein Assay), as further described below, in section 4.4.1.. PBS was 
used as a Blank. Then, for each sample, the volume corresponding to 1 µg of EVs’ protein 
was vigorously vortexed and aspired to a syringe at a constant speed, into a NanoSight 
NS300 system (Malvern Instruments, U.K.). This equipment makes a fast video capture and 
its particle-tracking software is able to measure the Brownian movement rate of the 
particles. All camera settings were fixed and maintained constant for all measurements. 
EVs’s size was inferred by the velocity of the particles (with the principle that smaller 
particles are faster than bigger particles). 
For EVs’ size distribution analysis it was preferentially used the mode parameter 
(although the program gives the mean and mode analysis), in order to exclude possible 
aggregates that can overestimate the results. 
 
28 
 
2.4.3. Transmission Electron Microscopy (TEM) 
 
The transmission electron microscope (TEM) allows visualization of EVs and thus 
confirming their presence in our experiment. Thereby, the EVs pellet obtained by 
ultracentrifugation was resuspended in approximately 50 μL of PBS. Then, 10 to 15 µL of 
this solution were added into Formvar-carbon coated electron microscopy grids for 1-2 min 
in the dark at RT (for coating). Samples were allowed to dry and 5 μL of uranyl acetate 
(contrasting solution) was added and the preparation was observed under a transmission 
electron microscope (TEM, Jeol JEM 1400) at an acceleration voltage of 80 kV. Data was 
obtained by the Histology and Electron Microscopy Service of IBMC/i3S, Porto. 
 
2.4.4. Detection of EVs markers (Western Blot) 
 
2.4.4.1. Protein extraction and quantification 
 
The EVs pellet obtained by ultracentrifugation was lysed in 30 μL of lysis Winman’s 
buffer (1% NP-40, 0.1 M Tris-HCl pH 8.0, 0.15 M NaCl and 5 mM EDTA) complemented 
with EDTA-free protease and phosphatase inhibitor cocktail (Roche), for 30 min at 4 ºC 
(with agitation). After centrifugation at 16 200 x g, during 10 min at 4ºC (Micro Star 17R, 
VWR), the supernatant (corresponding to the proteins) was collected and protein was 
quantified using a method based on the Lowry protocol (Bio-Rad DC™ Protein assay). The 
appropriate standards of bovine serum albumin (BSA, from Sigma-Aldrich, Co.) were used 
to generate a standard curve and ultrapure H2O was used as Blank. Absorbance was 
measured in a microplate reader at 655 nm after 15-30 min incubation in the dark. 
 
2.4.4.2. Protein expression analysis by Western Blot (WB) 
 
After protein quantification, 5 to 10 μg of EVs’ protein lysates were mixed with 
Loading Buffer (Tris-HCl 1 M, 5% SDS, 12% Glicerol, 12% β-mercaptoethanol and 0.024% 
bromophenol blue), boiled for 5 min at 95ºC (for protein denaturation) and separated on 
8%, 10% or 12% Tris-glycine SDS-Page polyacrylamide gels at 70 V (for at least 30 min) 
followed by approximately 1 h and 30 min at 100 V. The running buffer used was prepared 
from a commercial 10x Tris/Glycine/SDS buffer solution (Bio-Rad). After the separation, 
proteins were transferred onto a nitrocellulose membrane (Amersham Protran 0.45 NC, GE 
Healthcare) for approximately 2 h at 100 V. Transfer buffer was prepared from the 
commercial 10x Tris/Glycine buffer solution (Bio-Rad) to which 20% of methanol was 
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added. All the procedure was done in a Bio-Rad Western Blot System. Before proceeding, 
membranes were stained with Ponceau S solution (Sigma-Aldrich, Co.) to guarantee that 
all wells were correctly loaded with the same amount of protein and to confirm the 
successful transference of the protein onto the membranes.  
Membranes were then blocked in TBS-T [a Tris-buffered saline solution with 0.1 % 
Tween-20 (Promega)], containing 5% (w/v) non-fat dry milk (Molico), for at least 30 min with 
agitation at room temperature (RT). Primary and secondary antibodies were prepared using 
this solution. Membranes were incubated with the primary antibodies for 1 h and 30 min at 
RT or overnight at 4ºC, washed 3 times in TBS-T during 10 min with agitation and then 
incubated with the corresponding secondary antibodies for 1 h at RT. The antibodies used 
and their corresponding dilutions were: anti-Syntenin-1 (S-31): sc-100336 1:200; anti-
CHMP4B (C-12): sc-82556 1:100; anti-Clathrin LCB (H-60): sc-28277 1:200; anti-Flotillin-1 
(F-3): sc-74567 1:1000 and anti-cytochrome c (7H8); sc-13560 1:1000, from Santa Cruz 
Biotechnology; anti-CD63 (EXOAB-CD63A-1) 1:1000, and anti-Hsp70 (EXOAB-Hsp70A-1) 
1:500, from System Biosciences. The loading controls used were anti-tubulin (T6074) 1:10 
000, from Sigma-Aldrich, Co. or anti-Actin (sc-1616) 1:2000, from Santa Cruz 
Biotechnology. The following secondary antibodies were used: goat anti-rabbit IgG-HRP 
(sc-2004); goat anti-mouse IgG-HRP (sc-2031); and donkey anti-goat IgG-HRP (sc-2020), 
from Santa Cruz Biotechnology, all of them at a dilution of 1:2000. After washing the 
membranes 3 times in TBS-T for 10 min, the signal from the membranes was detected 
using the ECL Western Blot Detection Reagents (GE Healthcare), the chemiluminescence 
Amersham Hyperfilm ECL (GE Healthcare) and the Kodak GBX developer and fixer (Sigma-
Aldrich, Co.). The intensity of the bands was analyzed using the software Quantity One – 
ID Analysis (Bio-Rad).  
Whenever necessary, stripping of the membranes was done. The stripping buffer 
used contained 10% methanol and 10% acetic acid (Sigma-Aldrich, Co.). Membranes were 
washed 15 min with TBS-T prior and after stripping. 
 
2.5. Analysis of BCR-ABL levels in cellular and EVs’ extracts 
 
2.5.1. BCR-ABL oncoprotein analysis by Western Blot 
 
Protein extraction, quantification and analysis were performed as described in the 
previous section. For the preparation of cellular extracts, approximately 1 mL of cellular 
suspension of KBM5 and KBM5-STI cell lines was centrifuged at 130 x g for 5 min, washed 
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with 1 mL PBS and centrifuged again at 200 x g for 5 min at 4 ºC. After removing the PBS, 
pellets were lysed in approximately 30 μL of lysis buffer. Then, 5 to 50 µg of cells’ protein 
lysates and 5 to 10 μg of EVs’ protein lysates were separated in a polyacrylamide gel and 
further transferred to a membrane.  
The following commercial primary antibodies were used: anti-c-Abl (24-11): sc-23 
1:100 and p-c-Abl (7.Tyr 412): sc-293130 1:100 (in this case, block was done in TBS-T 
containing 5% (w/v) of BSA) from Santa Cruz Biotechnology. The loading controls and the 
secondary antibodies were the same as mentioned before. 
 
2.5.2. BCR-ABL mRNA  
 
2.5.2.1 RNA extraction 
 
Suspension cells (5-10 x 106 cells) were pelleted by 800 x g centrifugation, 10 min, 
and the supernatant discarded. Then, it was added 1.5 mL Trizol ™ Reagent (Ambion) and 
the pellet was vigorously homogenized, on ice, in order to completely disrupt the cells. After 
incubation of the homogenate for 5 min at RT, 200 μL of chloroform (Sigma-Aldrich, Co.) 
per 1 mL Trizol was added and the mixture was stirred and vortexed vigorously. The mixture 
remained 2-3 min incubating at RT, to allow the total dissociation of the nucleoprotein 
complexes. After the centrifugation at 12 000 x g for 15 min at 4°C, a separation of phases 
occurred: an upper aqueous phase containing RNA; a white interphase with DNA and 
proteins; and a lower red phase corresponding to organic reagents. The colorless top layer 
was transferred to a fresh tube, and 500 μL of isopropanol (Sigma-Aldrich, Co.) per 1 mL of 
Trizol were added for lysis (RNA precipitation). Samples were incubated in this solution 
overnight at 4ºC and then centrifuged for 10 min at 12 000 x g at 4ºC. After removal of the 
supernatant, precipitated RNA was washed in approximately 1 mL of cold 75% ethanol 
(Fisher Chemical) per 1 mL of Trizol initially added and centrifuged at 7 500 x g at 4ºC for 
5 min. Ethanol was removed and the pellet was left air drying until it got colorless, when it 
was immediately resuspended in 10-25 μL ultrapure water (depending on pellet size). 
RNA yield and quantification were assessed by spectrophotometry at 260 and 280 
nm, using NanoDrop™ 1000 Spectophotometer (Thermo Scientific). A 1% agarose 
(SeaKem® LE Agarose, Lonza) gel electrophoresis, stained with GreenSafe Premium 
(NZYTech, 3 μL for each 100 mL of solution), was performed to verify RNA quality (absence 
of DNA contamination and RNA degradation). TBE buffer (Tris/Borate/EDTA, from Grisp) 
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was used to prepare the gel and also used as electrophoresis buffer. Loading buffer Orange 
G (Sigma-Aldrich, Co.) was added to each sample and the running was performed at 100 
V during approximately 30 min. The gel was visualized by a gel transilluminator, GeldocTM 
XR+, using the Image Lab software (BioRad).  
The same procedure was performed to RNA extraction from EVs, but some 
additional steps were carried out prior it in order to remove extra RNA that might be outside 
of the EVs (and so, the analysis be only from the RNA inside of EVs) [145].  
For that, proteinase K (0.05 μg/μL, from Sigma-Aldrich, Co.) was added to the 
isolated EVs and incubated for 10 min at 37ºC. Then, to inhibit its activity, 5 mM of 
phenylmethylsulfonyl fluoride (PMSF, from Sigma-Aldrich, Co.) were added for 10 min at 
RT. In order to further inactivate proteinase K activity, the mixture was incubated at 90ºC 
for 5 min. Then, RNAse A (0.5 μg/μL, from Thermo Fischer Scientific) was added to the 
samples and incubated for 20 min at 37ºC, in order to unprotected RNA be degraded. 
Ultimately, RNA was extracted as described formerly.  
All the purified RNA samples were stored at -80ºC. During extraction, every step 
was performed at a cleaned workplace to avoid RNAse contamination, inside a hotte prior 
cleaned with ethanol 70% and/or with RNAse away solution (Sigma-Aldrich, Co.). Filtered 
tips were used.  
 
2.5.2.2. BCR-ABL quantification  
 
To assess the presence and copy numbers of BCR-ABL in cells and EVs, 
complementary DNA (cDNA) synthesis by reverse transcription and quantitative Real Time-
Polymerase Chain Reaction (qRT-PCR) were performed from 1 μg of RNA of each sample. 
This procedure was carrying out by our team collaborators from the Department of 
Hematology of Hospital São João (Oporto). In addition, ABL1 was used as reference gene 
and the percentage of BCR-ABL was obtained in relation to it.  
 
2.6. Co-culture of sensitive cells with EVs released by their drug resistant 
counterparts 
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Isolated EVs obtained by ultracentrifugation were resuspended in 100 μL of PBS, 
quantified using the modified Lowry protocol (as mentioned above in section 2.4.4.1.) and 
frozen at −80°C.  
In order to verify if the KBM5 cells (sensitive cells) gain resistance to STI571 
following incubation with EVs released by the resistant cells (KBM5-STI), co-culture 
experiments were performed. For that, co-culture was done in 3 different 96-well plates, 
with 80 μL per well of KBM5 and KBM5-STI cells seeded at a cellular density of 1.5 x 105 
cells/mL and 8.0 x 105 cells/mL, depended on the experiments. After approximately 12 h 
and 24 h, cells suffered different treatments: both resistant and sensitive cells were treated 
with PBS (as a control), KBM5 cells were treated with EVs released by themselves (as a 
control) and KBM5 cells were treated with EVs released by their resistant counterpart cells 
(KBM5-STI) during different times (6 h, 24 h or 48 h). An additional plate was used as a 
control of cell growth (named T0 plate), in order to have information on cells proliferation 
from the beginning to the end of the experiment. Therefore, the cell growth in the T0 plate 
was read 24 h after plating, by addition of resazurin. The amount of EVs used in the same 
experiment was equal, but different amounts were tested (5 µg, 10 µg and 15 µg) in different 
experiments. At the end of the above indicated time points (6 h, 24 h or 48 h), all conditions 
were incubated with STI571 for further 24 h or 48 h. In the end, the percentage of 
metabolically active cells was assessed with the resazurin assay, as describe above in 
section 2.2.2.1.. Annex 2 outlines the general schematic representation of the plate used 
for these experiments.  
In addition, co-culture experiments were performed using RPMI medium with 10% 
of depleted FBS (vesicles-free serum) and 1% of Antibiotic Antimycotic Stablized Solution 
(Sigma-Aldrich, Co.). 
 
2.6.1. Optimization of KBM5 and KBM5-STI cells concentrations to be plated 
 
The determination of the ideal cell concentration to be plated in the 96-well plates 
for KBM5 and KBM5-STI cell lines was performed. Thus, different cell concentrations were 
tested: 2.5 x 104, 5 x 104, 8 x 104, 1.5 x 105, 3 x 105 and 6 x 105 cells/mL. This experiment 
was performed for three different time-points, as explained above. The following protocol 
was used: in 3 different 96-well plates (for the 3 different time-points) 80 μL of different cell 
concentrations of KBM5 and KBM5-STI cell lines were plated per well (prepared by 
successive dilutions from the higher concentration). The Blank treatment consisted of 80 μL 
of culture medium only. Cells were then incubated during 24 h, 48 h or 72 h, and after that 
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10 μL of medium was added per well (corresponding to the volume of compounds that will 
be added in further experiments). Cells were incubated for another 48 h. Then, half of the 
volume from each well was collected for cell counting by trypan blue exclusion assay and 
the other half was used in the resazurin assay.  For that, resazurin solution at 0.1 mg/mL 
was added to each well at 1:9 proportion. The plates were incubated and read as mentioned 
in section 2.2.2.1.. The schematic representation of the plate is shown in Annex 3.  
 
2.7. Statistical analysis 
Data were summarized by means and standard errors of the means for symmetric 
distributions in continued variables. For data normally distributed, the statistical analyses 
were performed using paired and unpaired two-tailed Student’s t-test. To consider a 
statistical significant data, a p value <0.05 was established. 
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III. Results  
and Discussion  
 
  
35 
 
3.1. Characterization of the counterpart pair of cell lines 
 
The cell lines used in this study were a pair of drug-sensitive (KBM5) and drug-
resistant (KBM5-STI571, or to simplify, from now on, KBM5-STI) counterparts. The resistant 
cell line was derived from the sensitive (parental) one by treatment with increasing 
concentrations of imatinib mesylate (STI571) during several months, until the selected cell 
line presented normal growth kinetics in the presence of 1 μM of the drug [70, 139, 140]. As 
previously referred, both cell lines were kindly provided to our group by the laboratory that 
established the resistant cells.  
KBM5 and KBM5-STI are Philadelphia chromosome positive cell lines. KBM5 cells 
were established from a 67-year-old female CML patient in the blastic phase of the disease. 
Treatment of the cells with low concentrations of STI571 for a long period of time allowed 
those scientists to select the cells that survived in presence of STI571. It was verified that 
the selected resistant cells had a T315I single point mutation in BCR-ABL, causing a 
substitution of a threonine by an isoleucine at the Thr-315 residue of ABL [140, 146]. 
 
 
Figure 10. Microscopic images (200X) of the KBM5 (A) and KBM5-STI (B) cell lines. Images 
were obtained using an inverted light microscope (Leica DMi1); both cell lines had been similar time 
in culture when the pictures were taken. 
 
In order to further study both cell lines, we started to confirm the IC50 described in 
the literature, using the resazurin assay. The ideal cell density to be plated had been 
previously optimized in our laboratory. Thus, 1.5 x 105 cells/mL of KBM5 and KBM5-STI cell 
lines (corresponding to the exponential phase of cell growth without reaching confluence 
during the period of the experiment) were seeded in each well and, after 48 h of drug 
treatment with different concentrations of STI571, the IC50’s were determined for each cell 
line. For each of the tested concentrations of the drug, the percentage of cells metabolically 
A B 
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active was calculated by normalization of the values obtained for drug-treatments with those 
obtained in cells growing in normal medium, without the presence of the drug. Moreover, 
the presence of DMSO in a volume equivalent to the highest drug concentration tested 
proved to be non-toxic.  
Results presented in Figure 11 and Table 1 confirmed the two distinct profiles of 
the counterpart pair of cell lines in response to treatment with STI571: KBM5 cells were 
sensitive to STI571 while the KBM5-STI cells were more resistant to STI571 treatment up 
to the highest concentrations of the drug used (20 μM – concentration to which both cell 
lines responded similarly). The concentration of STI571 that inhibited the metabolic activity 
of KBM5 cells by 50% was 0.11 μM, while for KBM5-STI cells was 11.57 μM. These results 
are similar to those published in the literature for these cell lines [140].  
 
 
 
 
 
 
 
 
Figure 11. Dose-response curves of KBM5 cells (green line) and KBM5-STI cells (red line) to 
imatinib mesylate (STI571). Cells were treated with different concentrations of STI571 and the 
percentage of cells metabolically active was assessed after 48 h of drug treatment, using resazurin 
assay. Results are the mean ± S.E. of 4 independent experiments. 
 
Table 1. The concentration of imatinib mesylate (STI571) that inhibits KBM5 and KBM5-STI 
cellular viability by 50% (IC50). These values were obtained by the interpolation from the obtained 
dose-response curves (i.e. interpolation of the straight line corresponding to YY=50 with each curve). 
Cell line IC50 ± S.E. (μM) 
KBM5 0.11 ± 0.01 
KBM5-STI 11.57 ± 1.30 
 
3.2. Characterization of Extracellular Vesicles (EVs) derived from the counterpart pair 
of cell lines 
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The EVs research area is relatively new, however several protocols for their 
extraction have been developed and optimized. Some of those protocols are based on the 
following: size exclusion chromatography, which uses columns with a stationary and mobile 
phase; immunoaffinity isolation, with microbeads; polymeric precipitation with commercial 
kits, e.g. ExoQuickTM; and ultracentrifugation, consisting of successive centrifugations until 
obtaining an EVs pellet [143] [147]. In this work, EVs derived from both cell lines were 
isolated by ultracentrifugation, the most commonly used method and the gold-standard 
technique for EVs isolation so far. The ultracentrifugation protocol is based on the particles’ 
size and consists of various differential centrifugation steps [148].  
Once the EVs are isolated, it is important to characterize them, not only to confirm 
the isolation of EVs but also to study their characteristics. Figures 12 to 15 show results 
from several analyses used for EVs characterization. EVs were characterized in terms of 
size (Figures 12 and 13 and Table 2) by DLS and NTA, in terms of morphology (Figure 
14) by TEM and in terms of protein content (Figure 15) by Western blot.    
Regarding the DLS results (Figure 12), it is possible to verify a particle size 
distribution from 10 to 1000 nm, similar for the EVs isolated from both cell lines. This range 
of sizes encompasses the sizes described for EVs (in which exosomes are about 30 to 100 
nm and microvesicles are about 50 to 1000 nm) [144]. In addition, we verified that the 
smaller vesicles (with less than or around 100 nm) were the main subpopulation of EVs 
extracted from both cell lines. Results from the DLS analysis were plotted as particle number 
vs size, instead of particle intensity vs size (the direct measurement of the Zetasizer 
equipment) since bigger particles diffract more light, which will be reflected in a higher peak 
in the graph of intensity, but that does not mean that this subpopulation of EVs is more 
abundant in the sample. 
Therefore, we used this representation of results (as particle number vs size) to 
avoid an incorrect interpretation.  
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Figure 12. Size distribution of EVs isolated from KBM5 (A) and KBM5-STI (B) cell lines, 
analyzed by DLS. Results are the mean of 3 independent experiments, analyzed with the Zetasizer 
software. 
 
According to NTA results, isolated EVs have a size ranging from 10 to 500 nm, with 
a prevalence of EVs with sizes of approximately 100 nm (Figure 13 and Table 2). 
Therefore, both NTA and DLS analysis indicate that the EVs extracted have the same 
prevalence of smaller vesicles (equal to or less than 100 nm). Of note, the NTA provides 
not only information regarding the EVs’ size distribution but also on EVs concentration 
(particles/mL). Results regarding the concentration of particles showed that there were no 
significant differences between the size distribution of the EVs isolated from the two 
counterpart cell lines (p>0.05, obtained from two-tailed unpaired Student’s t-test) (Table 2). 
These results are in accordance with the ones obtained by the Lowry-based method (which 
allowed quantifying the total protein content of EVs) previously used to quantify 1 μg of 
protein and inject the corresponding volume in the equipment for NTA analysis. Since the 
same amount of protein was injected for all samples and the same amount of particles per 
mL were obtained in the NTA analysis, we concluded that both methods are useful to 
quantify EVs. 
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Figure 13. Size distribution of EVs isolated from KBM5 (A) and KBM5-STI (B) cells, analyzed 
by NTA. Each graph is representative of 3 independent experiments, generated by Nanosight 
software.  
 
Table 2. Summary of the parameters measured by NTA of EVs isolated from KBM5 and KBM5-
STI cell lines. Results are the mean of 3 independent experiments, generated by Nanosight 
software.  
Cell line-derived EVs 
Mean  
± S.E. (nm) 
Mode  
± S.E. (nm) 
Concentration  
± S.E. (particles/mL) 
KBM5 154.8 ± 6.4 105.0 ± 9.0 3.36 x 108 ± 4.75 x 107 
KBM5-STI 193.2 ± 4.2 129.2 ± 8.2 4.58 x 108 ± 5.55 x 107 
 
Another technique used to characterize EVs is TEM. This methodology allows the 
visualization of the structure, shape and size of EVs. Thereby, the presence of EVs following 
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the isolation protocol was further confirmed by TEM. In Figure 14, it is possible to observe 
the cup shape vesicles of different sizes, by negative staining. Thus, it was possible confirm 
that EVs from KBM5 and KBM5-STI cells were successfully isolated using the 
ultracentrifugation methodology. In addition, we verified that EVs released by KBM5 and 
KBM5-STI cells are mainly composed of small-size EVs. 
 
A                                                                            B 
 
Figure 14. Morphology of EVs isolated from KBM5 (A) and KBM5-STI (B) cells, analyzed by 
TEM. Images are representative of 2 independent experiments. Red arrows indicate the EVs 
detected with this methodology. Scale bar = 100 nm. 
 
Next, in order to characterize those EVs released by KBM5 and KBM5-STI cells, we 
investigated the presence of EV markers by Western blot analysis. Some classical markers, 
mostly involved in EVs biogenesis, were analyzed. Particularly, the markers studied were 
membrane-bound proteins, namely the tetraspanin CD63, CHMP4B (the component of the 
endosomal sorting complex required for transport, ESCRT III) and cytosolic proteins such 
as the heat-shock protein HSP70, syntenin-1 and flotillin-1 [109, 143, 144]. 
The cytochrome c (cyt c), a cell organelle marker, was assessed in order to exclude 
possible cellular debris contamination in the population of isolated EVs and thus was used 
as a negative control.   
Cytoskeletal proteins, like actin and tubulin, are frequently used as loading controls 
for cellular extracts. Nevertheless, it is not easy to find a good protein that may act as 
housekeeping in the case of EVs, since their cargo varies depending on the donor cell and 
is not an exact representation of the donor cell components. For that reason, some authors 
do not include loading controls for EVs protein lysates and, in some cases, they show the 
Ponceau staining instead, as prove of the amount of protein loaded into each well [149]. 
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In fact, Western blot is a challenging procedure in the EVs field, since it is necessary 
to start from a substantial amount of biological material (high quantity of cells from several 
culture flasks) in order to obtain an achievable amount of EVs extracts and enough protein 
to load a gel.  
As shown in Figure 15, we observed the presence of all the studied EVs markers in 
the EVs released from KBM5 and KBM5-STI cells. In addition, it was possible to confirm 
the absence of cellular contaminants, by the lack of detection of cyt c in the EVs extracts. 
Thus, we confirmed the presence of EVs in our extracts isolated by ultracentrifugation.   
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Analysis of several classical EVs markers in KBM5 and KBM5-STI cells and in the 
EVs released by those cells, by Western blot. Cells and EVs have the same amount of protein 
loaded in each case. Blots are representative of 1 (clathrin LCB), 2 (CHMP4B and cyt c), 3 (flotilin-
1), 4 (syntenin-1) or 5 (CD63 and Hsp-70) independent experiments. Cytochrome c was used as 
control for cellular content. Tubulin and actin were used as loading controls. 
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Taking together this part of the work, the results obtained here allowed to assure 
that EVs were successfully isolated by ultracentrifugation, given the size-ranges of the 
isolated particles (10-1000 nm), the presence of EVs markers and the absence of cellular 
contaminants. Furthermore, the EVs released from both KBM5 and KBM5-STI cell lines 
presented similar sizes (mainly small EVs) and protein markers. 
To the best of our knowledge, the characterization of EVs isolated from KBM5 and 
KBM5-STI cell lines has never been described before.  
 
It is important to note that the EVs research field has grown immensely in the past 
decade, together with its challenges and associated complexity. The need for a transparent 
and unambiguous interpretation and presentation of results relating to EVs was already 
noticed and the scientific community has been making an effort for standardization of the 
most possible parameters, from practical issues (such methods of EVs isolation and 
analysis), to the treatment of the results, in order to facilitate their comparison and repetition. 
However, the implementation of such practices is still an ongoing international effort [150-
153]. 
 
3.3. Investigation of BCR-ABL levels in the counterpart pair of cell lines and in the 
EVs released by those cells 
 
As BCR-ABL is a key protein of the tumorigenesis of Chronic Myeloid Leukemia 
(CML), we investigated if cells were exporting this protein by packaging it into the cargo of 
their EVs. Thus, BCR-ABL protein content was analyzed in KBM5 and KBM5-STI cells and 
in the EVs released by those cells (Figure 16A). In addition, the whole cell lysate from K562 
cells (a Philadelphia chromosome positive cell line derived from a CML patient in blastic 
phase) was used as positive control. The MCF-7 cell line was used as negative control, 
since this breast cancer derived cell line does not express BCR-ABL. The presence of EVs 
markers (CD63 and HSP70) was also studied. Ponceau staining was used to show the 
correct loading of the gel and subsequent transfer to the membrane (Figure 16B).  
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Figure 16. Analysis of BCR-ABL protein content in EVs and cells, by Western blot (A) and 
corresponding Ponceau protein staining (B). In the first six lanes, 5 μg of protein were loaded. In 
the last two lanes 20 μg of protein were loaded. The extracts from K562 and MCF-7 cell lines were 
used as positive and negative controls for BCR-ABL detection, respectively. CD63 and HSP70 are 
two classical EVs markers. Actin was used as loading control. The antibody used to recognize the 
BCR-ABL protein was c-Abl (24-11): sc-23, from Santa Cruz Biotechnology. 
 
Results (Figure 16) showed that, for the same amount of protein loaded (5 μg), the 
BCR-ABL protein was detected in EVs shed by KBM5 and KBM5-STI cells but not in the 
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cellular extracts of those cells, when using the antibody c-Abl (24-11): sc-23, from Santa 
Cruz Biotechnology. In addition, even when increasing the amount of protein 4 times (to 20 
μg), the BCR-ABL protein was not detected in those cells with this antibody. Thus, it seems 
that the BCR-ABL protein is being selectively packaged into the EVs shed by these cells. 
This is an interesting mechanism of oncoprotein shedding, previously described for other 
oncoproteins such as KIT [154], EGFR [155], KRAS and BRAF [156, 157] (the last two in 
their mutant form), with impact in pathways that lead to tumor progression. On the other 
hand, the absence of BCR-ABL detection in the cells when only 5 µg of protein were 
analyzed could be explained by the small amount of total cellular protein loaded. Indeed, it 
seems that BCR-ABL might be selectively packaged into EVs and therefore enriched in 
those vesicles when compared to the total protein content of the EVs.  
Indeed, with this antibody, BCR-ABL was only detected in cells when much larger 
amounts of protein were loaded into the Western blot (30 μg or 50 μg of cellular extract, 
Figure 17). In addition, the normal tyrosine kinase protein c-Abl, which is present in all cells, 
was also detected in this case. 
 
 
 
 
 
 
 
 
Figure 17. Analysis of BCR-ABL and c-Abl protein content in KBM5 and KBM5-STI cells, by 
Western blot. A total of 30 μg (left) or 50 μg (right) of cellular protein from KBM5 and KBM5-STI 
cells were loaded. Actin was used as loading control. The antibody to recognize the BCR-ABL protein 
used was c-Abl (24-11): sc-23, from Santa Cruz Biotechnology. 
 
The detection of BCR-ABL protein was further confirmed by using another BCR-ABL 
antibody, the p-c-Abl (7.Tyr 412): sc-293130, from Santa Cruz Biotechnology. Although very 
faint, a band was detected in both EVs from KBM5 and KBM5-STI cells, confirming the 
presence of the oncoprotein in these nanoparticles, as shown in Figure 18. Again, the 
positive and negative controls for BCR-ABL were K562 and MCF-7 cells, respectively. 
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Flotillin-1 is an EV marker, whose detection proved the presence of EVs, and actin was 
used as loading control, which showed to be only effective in the case of cellular extracts.  
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Analysis of BCR-ABL protein content in EVs, by Western blot (A) and respective 
Ponceau protein staining (B) of the lanes corresponding to EVs. 5 μg of EVs and cells were 
loaded.  The cellular extracts of K562 and MCF-7 were used as positive and negative controls for 
BCR-ABL detection, respectively. Flotillin-1 is a classical EVs marker. Actin was used as loading 
control. The antibody to recognize the BCR-ABL protein used was p-c-Abl  
(7.Tyr 412): sc-293130, from Santa Cruz Biotechnology. 
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Taken together, these results confirm that the BCR-ABL protein is selectively 
packaged into EVs which are released from these drug sensitive and drug resistant cells.  
 
Following, it was decided to investigate if the BCR-ABL mRNA was also packaged 
into the EVs. Thereby, RNA from cells and EVs was extracted and analyzed by qRT-PCR 
for BCR-ABL1. ABL1 was used as reference gene. This work was performed by a 
collaborator from Centro Hospitalar São João - Porto. 
Preliminary results (from one experiment only) suggest that BCR-ABL mRNA was 
also present in EVs released by both cell lines, in a proportion (relative to the reference 
gene – ABL1) similar to the one found in cells (Table 3). These results were confirmed by 
nested PCR (results not shown). 
 
 
Table 3. Copy numbers of BCR-ABL1 and ABL1 transcripts detected in cells and EVs. 
Preliminary results were obtained by qRT-PCR and are from 1 experiment only.  
 
Copy number of 
BCR-ABL1 
transcript 
Copy number of 
ABL1 transcript 
KBM5 Cells 298603.44 416970.25 
KBM5-STI Cells 343242.19 463391.59 
KBM5 EVs 43.3 63.14 
KBM5-STI EVs 584.72 874.48 
 
The packaging and release of EVs by K562 cells, containing BCR-ABL gene, 
transcript and protein was previously demonstrated by other authors, both in vitro and in 
vivo [158, 159]. 
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3.4. Effect of co-culture of sensitive cells with EVs released by their drug resistant 
counterparts 
In order to verify if drug-resistant cells transfer resistance to drug sensitive cells, 
mediated by EVs, co-culture experiments were performed with EVs from drug resistant 
donor cells with drug sensitive recipient cells. These experiments proved to be a major 
challenge, since many parameters needed to be optimized throughout the work. 
Nevertheless, co-culture systems have proved to be a useful tool to study cell to cell 
interactions, to test delivery systems and new drug candidates, among others [160-164]. 
The resazurin assay was performed to assess cellular viability during these 
experiments. This is a simple, relatively fast and economical method [142]. Moreover, it is 
believed that resazurin is metabolized in the mitochondria [165], thus ensuring that a 
possible metabolic activity in the EVs will not interfere with the reading of the fluorescence 
values.  
Therefore, the sensitive cell line (KBM5) was co-cultured with EVs released from its 
drug resistant counterpart cell line (KBM5-STI), and further treated with STI571. However, 
to start those experiments, some conditions needed to be tested. Thus, a preliminary study 
was performed using different incubation periods of KBM5 cells with EVs released from 
KBM5-STI cells, under different drug treatment durations and different drug concentrations 
(as explained in Scheme 1). The amount of EVs incubated was maintained constant in all 
plates, being of 5 μg per well. The concentrations of STI571 used were:  approximately the 
IC25, IC50 and IC75 for KBM5 cells in the plates where the cells were in contact with the 
drug for a longer time (48 h, plates 1 and 3); the IC50, IC75 and IC85 for KBM5 cells in the 
plates in which cells were treated with drug for 24 h (plates 2 and 4). Those concentrations 
of STI571 were previously determined, by interpolation of the graph shown in Figure 11 
(section 1).  
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Scheme 1. Description of the workflow of the preliminary co-culture experiment (4 plates) of 
KBM5 cells with EVs derived from the drug-resistant cell line, KBM5-STI. In all plates, EVs were 
added only 24 h after seeding the cells, to allow time for the cells to “adapt” to the new environment. 
Plates’ reading was done after 4 h of incubation with resazurin.  
 
From the results shown in Figure 19, it was possible to infer that there were no 
differences among the treatments tested, in what concerns response to STI571. However, 
this was only a preliminary experiment and important controls were missing from this 
experiment, such as sensitive cells alone and co-cultured with their own EVs and others 
which were included in subsequent experiments (indicated below). 
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Figure 19. Dose-response curves to STI571, of drug sensitive cells (KBM5) following co-
culture with 5 μg of EVs released by KBM5-STI cells.  The concentrations of STI571 used were: 
0.040 μM, 0.080 μM, 12 μM and 18 μM (approximately the IC25, IC50, IC75 and IC85 for KBM5 
cells, respectively). Cells were plated for 24 h and then divided in 4 conditions: Plate 1: 12 h 
incubation with EVs followed by 48 h incubation with STI571; Plate 2: 12 h incubation with EVs 
followed by 24 h incubation with STI571; Plate 3: 24 h incubation with EVs followed by 48 h incubation 
with STI571; Plate 4: 24 h incubation with EVs followed by 24 h incubation with STI571 treatment. 
Results represent 1 independent experiment only. The concentration of cells seeded was 1.5 x 105 
cells/mL. The % of cells metabolically active was determined using the resazurin assay (fluorescence 
read at 530 and 590 nm).  
 
Thus, further experiments were conducted, with the longer incubation periods with 
EVs (24 h, since longer co-culture would probably be necessary to transfer drug resistance) 
followed by 24 h drug treatment (since it was believed that the effect would be visible shortly 
after the co-culture). Important controls were included in these co-culture experiments, such 
as: KBM5 cells without the presence of EVs (in this case cells incubated with PBS); KBM5 
cells with EVs derived from their own cells (KBM5 + EVs S) and KBM5-STI cells only. These 
controls allowed to study the metabolic activity of the drug sensitive cell line, as well as to 
understand if EVs could interfere with the normal growth of the cells. In addition, a growth 
control was included with KBM5 cells without the presence of STI571 but with DMSO 
(solvent/vehicle of STI571).  
As can be seen in Figure 20, the co-culture of sensitive cells (KBM5) with EVs 
released by either of the cell lines (resistant or sensitive to STI571) did not alter the 
response of the recipient cells to STI571. As expected, KBM5-STI cells were more resistant 
to STI571 than KBM5 cells. Therefore, under the conditions tested, the EVs released by the 
drug-resistant cells had no effect on the response of KBM5 cells to STI571.  
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Figure 20. Dose-response curve to STI571 of drug sensitive cells (KBM5) following co-culture 
with 5 μg of EVs released by KBM5-STI cells (corresponding to the graph line KBM5 + EVs R). 
The concentrations of STI571 used were: 0.10 μM, 12 μM and 18 μM (approximately the IC50, IC75 
and IC85 of KBM5 cells, respectively). Cells were plated for 24 h and then incubated 24 h with EVs 
followed by 24 h incubation with STI571 treatment. The wells with KBM5 cells only, KBM5 cells 
incubated with EVs from themselves (EVs S) and KBM5-STI cells only were used as references. 
Results represent 1 independent experiment only. The concentration of cells seeded was 1.5 x 105 
cells/mL. The % of cells metabolically active was determined using the resazurin assay (fluorescence 
read at 530 and 590 nm).  
 
Thereby, other parameters that might influence drug-resistance and not taken into 
account in the previous experiments were tested in the following experiments. Indeed, other 
incubation periods of the EVs with sensitive cells (KBM5) were tested (prior to the addition 
of STI571), such as 6 h, 24 h and 48 h. In addition, STI571 treatment was kept for 48h 
independently of the co-culture incubation period. The reason for treating cells for 48 h with 
STI571 is because the IC50 of the STI571 was previously determined at 48 h. Once again, 
5 μg of EVs were added per well. The new workflow is shown in Scheme 2. 
  
 
  
 
 
 
 
 
 
 
 
 
 
Scheme 2. Description of the workflow of the co-culture experiment (3 plates) of KBM5 cells 
with EVs derived from the drug-resistant cell line, KBM5-STI. In all plates, EVs were added only 
24 h after seeding the cells, to allow time for the cells to “adapt” to the new environment. Plates’ 
reading was done after 4 h of incubation with resazurin.   
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As shown in Figure 21, under all the different condition tested, no effect of the co-
culture of EVs released by drug-resistant cells was verified in the sensitive (KBM5) cells. 
The dose-response curves to STI571 of KBM5 cells and KBM5 cells incubated with EVs 
(released by either KBM5 or KBM5-STI cells) remained the same. Therefore, under the 
conditions described above for this experiment, it was again verified that EVs released by 
the resistant cell line had no effect on the metabolic activity of the sensitive (KBM5) cells 
under STI571 treatment.  
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Figure 21. Dose-response curves to STI571 of drug sensitive cells (KBM5) following co-
culture with 5 μg of EVs released by KBM5-STI cells for 6 h (A), 24 h (B) and 48 h (C) 
(corresponding to graph line KBM5 + EVs R). The concentrations of STI571 used were: 0.10 μM, 12 
μM and 18 μM (approximately the IC50, IC75 and IC85 of KBM5 cells, respectively). Cells were 
plated for 24 h and then incubated 6 h, 24 h or 48 h with EVs followed by 48 h incubation with STI571 
treatment. The wells with KBM5 cells only, KBM5 cells incubated with EVs released by themselves 
(EVs S) and KBM5-STI cells only were used as references. Results represent 2 independent 
experiments. The concentration of cells seeded was 1.5 x 105 cells/mL. The % of cells metabolically 
active was determined using the resazurin assay (fluorescence read at 530 and 590 nm). 
 
One possible explanation for the lack of effect observed during the different 
conditions tested could be that the cells reached confluency or lack of nutrients during the 
course of the experiment. For that reason, in order to guarantee that cells were 
exponentially growing during the course of the experiments, the previous experiments were 
repeated including a T0 plate, that is, a plate in which cellular metabolic activity was 
measured at the beginning of the experiment.  
Results showed that the magnitude values of fluorescence obtained from the 
resazurin assay were similar for the plate analyzed at T=0h (T0) and the other plates which 
were analyzed following different times of incubation (plates 1, 2 and 3). These results 
suggest that the plateau of the fluorescence curve might have been attained during some 
of the previous experiments (when longer co-culture and drug-treatment times where 
studied). This means that the fluorescent values read might not have been in the linear 
response area of the resazurin assay. In summary, these results suggest that the 
fluorescence values obtained in the previous experiments might not have been directly 
correlated with the metabolic activity of cells. Indeed, during the course of this work, a new 
batch of the resazurin reagent was purchased, which might have provided different 
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fluorescent readings from the initial batch. Therefore, the initially optimized conditions 
(optimized by other members of the team prior to the initiation of this work) for the resazurin 
assay might not have been maintained throughout some of the previous experiments. 
Thus, in order to decrease the fluorescence readings of the cells in the resazurin 
assay and, in this manner, to guarantee that the work was performed during the exponential 
growth phase of the cells, optimization of the conditions for the resazurin assay was again 
performed. The ideal concentration of cells to be seeded (not reaching the plateau of 
fluorescence values by the end of the co-culture experiment) was studied, using the new 
batch of resazurin reagent and up to 120 h of total experiment duration (i.e. total duration 
of cells in culture). Since the previous experiments were started with 1.5 x 105 cells/mL 
(which was the previously optimized conditions for the previous resazurin batch and 
experiments for up to 48 h of duration), lower concentrations of cells were tested. 
Results are presented in Figure 22, which indicate that, for both cell lines, the 
concentration of cells used in the previous experiments (1.5 x 105 cells/mL), in which the 
total duration of the experiments was as long as 96 h (Plate 2) or 120h (Plate 3), were at 
the beginning of the plateau phase i.e. at the limit of the linearity of the assay. Thus, there 
was a possibility that the previously observed lack of effect of the EVs released by drug-
resistant cells in the drug sensitive cells was due to this methodological problem, but only 
when the duration of the experiments was as long as 96h or 120h. Therefore, results from 
Figure 22 indicate that the ideal cell density to be used in co-culture experiments of up to 
96 or 120h should be 8.0 x 104 cells/mL. This cell density allows cells to be at the 
exponential phase of the growth curve during the total duration of the experiment. 
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Figure 22. Optimization of the ideal concentration of cells to be seeded of KBM5 (A) and 
KBM5-STI (B) cells in a 96-well plate during the total duration of co-culture experiments.  Total 
time in culture – Plate 1: 78 h, Plate 2: 96 h, Plate 3: 120 h. Results were obtained using the resazurin 
assay (fluorescence read at 530 and 590 nm). The concentrations tested were the following: 2.5 x 
104, 5.0 x 104, 8.0 x104, 1.5 x 105, 3.0 x 105 and 6.0 x 105 cells/mL. Results represent 1 independent 
experiment only. Results were further confirmed by trypan blue exclusion assay and flow cytometry 
(data not shown). 
 
Therefore, further co-culture experiments were conducted, by seeding 8.0 x 104 
cells/mL, and decreasing the concentration of STI571 to 6.2 μM, 3.1 μM and 0.20 μM, (this 
last concentration being close to the IC50 of KBM5 cells). In addition, new aliquots of STI571 
were prepared (to avoid possible drug instability problems). The workflow of the co-culture 
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experiment was maintained as before, represented in Scheme 2, but including the 
alterations referred above (number of cells plated and new aliquots of STI571).  
In spite of the methodological alterations performed, the obtained results (Figure 
23) showed that EVs released by KBM5-STI cells had no effect on the percentage of KBM5 
cells metabolically active in the presence of STI571, i.e. had not effect of the response of 
the sensitive cells to STI571. Thus, these results were in agreement with the previously 
obtained results (Figures 20 and 21). Moreover, and surprisingly, it was possible to observe 
that the drug response of the resistant (KBM5-STI) cells was closer to the drug response of 
the sensitive (KBM5) cells in the longer co-culture experiment (Plate 3). Even though this 
result would need to be repeated in order to be confirmed, it is possible that this was caused 
by the longer incubation period of this plate. For this reason, in further experiments Plate 3 
was removed from the study.  
A  
 
 
 
 
 
 
 
 
 
B 
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Figure 23. Dose-response curves to STI571 of drug sensitive cells (KBM5) following co-
culture with 5 μg of EVs released by KBM5-STI cells for 6 h (A), 24 h (B) and 48 h (C) 
(corresponding to graph line KBM5 + EVs R). The concentrations of STI571 used were: 0.20 μM, 3.1 
μM and 6.2 μM. Cells were plated for 24 h and then incubated 6 h, 24 h or 48 h with EVs followed 
by 48 h incubation with STI571 treatment. The wells with KBM5 cells only, KBM5 cells incubated with 
EVs released by themselves (EVs S) and KBM5-STI cells only were used as references. Results 
represent 1 independent experiment only. The concentration of cells seeded was 8.0 x 104 cells/mL. 
The % of cells metabolically active was determined using the resazurin assay (fluorescence read at 
530 and 590 nm). 
 
In an attempt to test more possible co-culture conditions and to try to better mimic 
the continuous effect (of EVs exposure) which might happen in the human body, 5 μg of 
EVs per well were added not only before STI571 treatment but also after drug treatment 
(Scheme 3). In this manner, a more frequent co-culture with EVs might better resemble the 
real conditions in the human body. Moreover, since the BCR-ABL protein has a half-life 
above 24h [166], these new conditions would ensure that the BCR-ABL from the EVs 
(probably both wild-type and mutated, the last conferring resistance to the cells) was more 
frequently co-incubated with the sensitive cells and, thus, would be present during the 
duration of the drug treatment. In addition, these new conditions allowed more EVs to be in 
co-culture with the recipient cells. 
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Scheme 3. Description of the general workflow of the co-culture experiment (2 plates) of KBM5 
cells incubated with EVs released by the drug-resistant cell line, KBM5-STI. In both plates, the 
first 5 μg of EVs were added 24 h after seeding the cells, to allow time for the cells to “adapt” to the 
new environment. Plates’ reading was done after 4 h of incubation with resazurin.  
 
Additionally, the effect of co-culturing 10 μg of EVs (from drug resistant cells) with 
the sensitive cells 6 h and 24 h prior the drug treatment was also tested (Scheme 4). 
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Scheme 4. Description of the general workflow of the co-culture experiment (2 plates) of KBM5 
cells incubated with EVs released by the drug-resistant cell line, KBM5-STI. In both plates, 10 
μg of EVs were added 24 h after seeding the cells, to allow time for the cells to “adapt” to the new 
environment. Plates’ reading was done after 4 h of incubation with resazurin. 
 
The obtained results (Figures 24 and 25) showed that EVs released by the drug 
resistant cells had no effect in the percentage of KBM5 cells metabolically active in the 
presence of STI571, i.e. had no effect in the drug response of the sensitive cells. This lack 
of effect was observed when EVs from drug resistant cells were more frequently co-cultured 
with the sensitive cells, both before and after drug treatment (Figure 24), and when the 
quantity of EVs co-cultured was increased to the double (10 μg of EVs before drug 
treatment; Figure 25).  
A 
 
 
 
 
 
 
 
 
 
B 
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Figure 24. Dose-response curves to STI571 of drug sensitive cells (KBM5) following co-
culture with 10 μg (5 μg + 5 μg) of EVs released by KBM5-STI cells (corresponding to graph line 
KBM5 + EVs R). 5 μg of EVs were added for 6 h (A) and 24 h (B) before STI571 treatment, and 5 μg 
were added again 24 h after the addition of STI571. The concentrations of STI571 used were: 0.20 
μM, 3.1 μM and 6.2 μM. The wells with KBM5 cells only, KBM5 cells incubated with EVs released by 
themselves (EVs S) and KBM5-STI cells only were used as references. Results represent 1 
independent experiment only. The concentration of cells seeded was 8.0 x 104 cells/mL. The % of 
cells metabolically active was determined using the resazurin assay (fluorescence read at 530 and 
590 nm). 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Figure 25. Dose-response curves to STI571 of drug sensitive cells (KBM5) following co-
culture with 10 μg of EVs released by KBM5-STI cells. 10 μg of EVs were added 6 h (A) and 24 
h (B) before STI571 treatment (corresponding to graph line KBM5 + 10 μg EVs R). The concentration 
of STI571 used was 3.1 μM. The wells with KBM5 cells and KBM5-STI cells only were used as 
references. Results represent 1 independent experiment only. The concentration of cells seeded was 
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8.0 x 104 cells/mL. The % of cells metabolically active was determined using the resazurin assay 
(fluorescence read at 530 and 590 nm). 
 
The last approach attempted in this work involved the addition of EVs released by 
KBM5-STI cells before, together with and after STI571 treatment (3 x 5 μg per well, i.e. a 
total of 15 μg of EVs added to the sensitive cells; Scheme 5). In addition, the intervals 
between the additions of EVs to the sensitive cells were slightly shortened, as well as the 
time allowed for cells to “adapt” to the new wells (after seeding and before co-culture with 
EVs). This new approach also allowed to test the co-culture with EVs (10 μg and 15 μg) 
together with the STI571 treatment (Scheme 6).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5. Description of the general workflow of the co-culture experiment of KBM5 cells 
with EVs released by the drug-resistant cell line, KBM5-STI. The EVs (5 μg) were added 10 h 
after seeding the cells, so that the cells could “adapt” to the new environment, as well as during and 
6 h after STI571 treatment. Plate reading was done after 4 h of incubation with resazurin.  
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Scheme 6. Description of the general workflow of the co-culture experiment of KBM5 cells 
with EVs released by the drug-resistant cell line, KBM5-STI. The EVs (10 and 15 μg) were added 
16 h after seeding the cells, so that the cells could “adapt” to the new environment. Plate reading 
was done after 4 h of incubation with resazurin.  
 
The results obtained are presented in Figures 26 and 27 and demonstrated that 
there were no alterations on the metabolic activity of sensitive (KBM5) cells following 
STI571 treatment, i.e. of response to STI571, following incubation with a total of 15 μg of 
EVs released by the drug-resistant cells, when compared with KBM5 cells without co-culture 
of EVs or with KBM5 cells incubated with EVs released by themselves. The same negative 
results were obtained when either 10 μg or 15 μg of EVs were added together with the 
STI571 treatment. 
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Figure 26. Dose-response curve to STI571 of drug sensitive cells (KBM5) following co-culture 
with 15 μg (5 μg + 5 μg + 5 μg) of EVs released by KBM5-STI cells (corresponding to graph line 
KBM5 + EVs R). 5 μg of EVs were added: 6 h before, together with and 6 h after drug treatment. The 
concentrations of STI571 used were: 0.20 μM, 3.1 μM and 6.2 μM. The wells with KBM5 cells only, 
KBM5 cells incubated with EVs released by themselves (EVs S) and KBM5-STI cells only were used 
as references. Results represent 1 independent experiment only. The concentration of cells seeded 
was 8.0 x 104 cells/mL. The % of cells metabolically active was determined using the resazurin assay 
(fluorescence read at 530 and 590 nm). 
 
 
 
 
 
 
 
 
 
 
Figure 27. Dose-response curve to STI571 of drug sensitive cells (KBM5) following co-culture 
with 10 and 15 μg of EVs released by KBM5-STI cells. 10 or 15 μg of EVs were added together 
with STI571 (corresponding to graph lines KBM5 + 10 μg EVs R and KBM5 + 15 μg EVs R, 
respectively). The concentration of STI571 used was 3.1 μM. The wells with KBM5 cells and KBM5-
STI cells only were used as references. Results represent 1 independent experiment only. The 
concentration of cells seeded was 8.0 x 104 cells/mL. The % of cells metabolically active was 
determined using the resazurin assay (fluorescence read at 530 and 590 nm). 
 
 
The results from all the co-culture experiments described in this thesis are 
summarized in Table 4. From these results we may infer that, in the cell lines studied and 
under the conditions studied, although BCR-ABL is present in the EVs released by donor 
drug resistant cells (as confirmed by the BCR-ABL protein and mRNA content analysis), 
this may not have impact on the resistance of recipient drug sensitive cells to STI571.  
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Table 4. Summary of the co-culture experiments stating similarities and differences among 
them. 
Figure  
[Cells] 
(cells/mL) 
[EVs] 
(μg) 
[STI571] 
(μM) 
Time of 
incubation with 
EVs (before 
STI571 treatment) 
(h) 
 
Duration 
of STI571 
treatment 
(h) 
 
20 1.5 x 105 5 0.10; 12; 18 24 24 
21 1.5 x 105 5 0.10; 12; 18 6, 24 and 48 48 
23 8.0 x 104 5 0.20; 3.1; 6.2 6, 24 and 48 48 
24 and 25 8.0 x 104 10 0.20; 3.1; 6.2 6 and 24  48 
26 and 27 8.0 x 104 15 0.20; 3.1; 6.2 6  48 
 
There are possible explanations for what might be happening at the molecular level. 
Firstly, it is possible that the recipient cells do not take up the EVs from the donor cells. 
Secondly, since it was not possible to verify if the BCR-ABL in the EVs was wild-type or 
mutated, it is possible that only wild-type BCR-ABL is present in the EVs. Thirdly, it is 
possible that if BCR-ABL is transferred to recipient cells, it may be non-functional in the 
recipient cells (thus not contributing to a drug-resistant phenotype in recipient cells). Finally, 
the EVs released by drug-resistant cells might not shed enough mutant BCR-ABL (mRNA 
and/or protein) to alter the drug response of recipient sensitive cells. All these possibilities 
could lead to the verified undetectable influence of the EVs released by drug-resistant cells 
on the drug response of sensitive recipient cells.  
However, other experimental conditions should be tested before taking final 
conclusions. For example, high fluorescence values were always read on the resazurin 
assay, even after decreasing the cell density of seeded cells. One possible reason for this 
is the time of incubation with resazurin (4 h), which may not have been the ideal (this time 
usually depends on cell growth). Therefore, the incubation time with resazurin could have 
been optimized for the cell lines used in this work and for the necessary duration of the 
experiments. In fact, the incubation time with resazurin varies between 1 h to 4 h, depending 
on the cell concentration and cell type (because of possible differences in the cellular rate 
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of proliferation). When a high number of cells are incubated with resazurin, for long periods, 
the fluorescent product of resazurin reduction, the resorufin, is in turn reduced to a non-
fluorescent product called hydro-resorufin [142]. Thereby, the value of fluorescence read 
will not reflect the number of cells present in the well. Therefore, the protocol for the 
resazurin assay should in future experiments be adapted to the cell lines and duration of 
the experiments necessary for this specific work.  
Another possible alteration to the co-culture experimental conditions is to further 
increase the amount of EVs added to each well. Although 3 different concentrations of EVs 
were tested, the proportion of EVs/cells may still need to be optimised. Nonetheless, it 
should be a compromise to balance this increase with the amount of EVs that would be 
biologically acceptable for the recipient cells. However, to our knowledge, there is no 
information on the literature on what would be considered physiological (or even 
pathological) concentrations of EVs delivered to recipient cells. In addition, an increase in 
the amount of EVs to be co-cultured would be technically quite difficult, requiring an even 
bigger number of donor (resistant) cells in culture for isolation of EVs.  
In summary, the co-culture experiments should be further optimized in order to allow 
definite conclusions. However, our preliminary results indicate that, under the conditions 
tested, there is no transfer of drug resistance mediated by the EVs released by these drug 
resistant cells to drug sensitive cells. 
Given the results here obtained, regarding the presence of BCR-ABL in the EVs 
shed by these leukemic cells, it would be interesting to confirm if those EVs (from either 
drug sensitive or drug resistant cells) may transfer BCR-ABL to non-tumor cells. Indeed, 
other authors have shown that BCR-ABL might be transferred to neutrophils and HEK293 
cells, human embryonic kidney cells, by contact with EVs from CML cells. Additionally, the 
same authors showed that this shedding of EVs containing BCR-ABL has physiological 
significance, since BCR-ABL present in EVs influenced the function of recipient cells. 
Furthermore, the injection of those EVs in immunodeficient mice had a strong impact, 
causing CML-like symptoms in those mice. Thus, this phenomenon might have an important 
role in tumor initiation and progression [158, 159]. Besides, another group has 
demonstrated that endothelial cells acquire both BCR-ABL oncoprotein and mRNA, after 
incubation with EVs released by BCR-ABL+ cells (either from plasma of recently diagnosed 
CML patients or from a CML cell line, K562) [167].  
Finally, the results here presented show that the EVs released by both (drug 
sensitive and drug resistant) cell lines have BCR-ABL on their cargo. In addition, the data 
presented also suggest that there is selective packaging of this oncogene into the EVs shed 
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by these cells. Unfortunately, it was not possible to sequence the mRNA or the protein in 
the EVs to confirm if they were wild-type or mutated. Future work will continue this study 
since there are obvious implications for the possible detection of BCR-ABL in circulating 
EVs from liquid biopsies of chronic myeloid leukemia patients. Indeed, the presence of this 
biomarker in circulating EVs may allow a more sensitive detection of BCR-ABL since each 
tumor cell sheds many more EVs. In addition, the cargo of the EVs is more stable from 
degradation by nucleases or proteinases [117], making EVs an optimal source of cancer 
biomarkers. 
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IV. Conclusion 
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4.1. Concluding Remarks  
 
The success of TKIs in treating CML highlighted the potential of targeting oncogenic 
kinases with small molecules. The discovery of STI571 caused a dramatically improvement 
in CML patients’ prognosis, transforming an irrevocably lethal disease into a paradigm of 
molecular target therapy [47]. Nonetheless, there is a relative high relapse rate following 
treatment with this drug, caused by resistance of leukemic cells to the drug. This drug 
resistance may have various causes or mechanisms, representing a serious clinical 
drawback [36, 56]. Hence, it is urgent to clearly identify mechanisms behind resistance of 
leukemic cells to STI571, in order to prevent this problem and to find new therapeutic targets 
that may contribute to counteract this very serious clinical problem.  
Many studies have suggested that EVs may contribute to the dissemination of 
cancer drug resistance, by transferring drug resistance traits from donor drug-resistant cells 
to sensitive cells [106, 138]. Indeed, it is known that the cargo of EVs released by drug 
resistant cancer cells contains proteins, microRNAs, mRNAs and other molecules from the 
donor cells and that this cargo is functional in recipient drug sensitive cells, being capable 
of altering the phenotype of recipient cells towards drug resistance [168, 169]. This is an 
emerging area of interest with possible impact on identification of novel approaches to 
predict and counteract drug resistance [117]. 
This work aimed at verifying if: i) EVs released by BCR-ABL positive leukemia cell 
lines had BCR-ABL (protein and mRNA) on their cargo; and ii) if drug resistance could be 
transferred from leukemic drug resistant cells (with mutant BCR-ABL) to leukemic drug 
sensitive cells (with wild-type BCR-ABL).  
In this work, the drug response profiles of a pair of drug sensitive (with wild-type 
BCR-ABL) and drug resistant (with mutant BCR-ABL) counterpart cell lines were initially 
confirmed (using the resazurin assay). By determining the dose-response curves and 
comparing the IC50 of STI571 in both cell lines, it was possible to confirm that KBM5-STI 
cells were resistant to STI571 (up to high concentrations of this drug) whereas KBM5 cells 
were sensitive to this drug.  
The characterization of the EVs isolated from this pair of cell lines allowed to confirm 
their successful isolation using an ultracentrifugation protocol. Indeed, DLS, NTA and TEM 
analysis confirmed that the obtained size-ranges were the ones expected for EVs (10 – 
1000 nm). The cup shaped morphology, typical of EVs, was also verified by TEM. 
Furthermore, by WB analysis, the presence of several EVs markers (such as CD63, HSP70 
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and Flotillin-1) and the absence of cellular contaminants were confirmed. Additionally, it was 
possible to verify that EVs released by both cell lines (sensitive and resistant to STI571) 
presented similar sizes and protein markers. 
Moreover, the BCR-ABL content was studied both on the counterpart cell lines and 
on the EVs released by those cell lines. Surprisingly, the results here obtained (by WB) 
suggest that the BCR-ABL protein is selectively packaged into EVs, providing a mechanism 
for oncoprotein shedding. In addition, preliminary results obtained as collaboration with 
Centro Hospitalar São João also suggest that the mRNA of BCR-ABL is packaged into 
those EVs. However, the presence of the mRNA needs to be further confirmed. 
The work presented in this thesis also investigated if there was a transfer of drug 
resistance mediated by EVs, from the drug resistant to the drug sensitive counterpart cells. 
For that, co-culture experiments were performed, based on the incubation of drug-sensitive 
cells (KBM5) with EVs released by drug-resistant cells (KBM5-STI). The EVs from donor 
cells were in contact with the recipient cells during different periods and in different 
concentrations; different times were also tested for addition of EVs to recipient cells. The 
dose-response curves to STI571 of the recipient cells (with or without incubation with EVs 
from donor cells) were assessed, in order to ascertain if KBM5 cells acquired drug 
resistance traits. Results from the different experiments carried out, under the different 
treatment times and conditions tested, did not show evidence for a transfer of drug 
resistance from resistant to sensitive cells. However, it is possible that under different 
experimental conditions the results obtained would be different. Unfortunately, due to 
technical and time constraints, it was not possible to verify if the BCR-ABL present in the 
EVs was wild-type or mutated.  
In summary, the main conclusion drawn from this work was that BCR-ABL is 
packaged into the cargo of EVs released by BCR-ABL+ leukemia cells (both sensitive and 
resistant to STI571). Nevertheless, although this transfer may be mediated by EVs released 
by drug-resistant cells, with mutant BCR-ABL, incubation of drug sensitive cells with those 
EVs did not influence drug response of recipient cells, under the conditions tested. More 
studies are required in order to investigate the relevance of BCR-ABL packaging into EVs 
and its impact in the progression of disease in drug resistance. 
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4.2. Future perspectives 
 
Firstly, in order to confirm the results obtained from the co-culture experiments, more 
conditions should be tested regarding the duration of cellular incubation with resazurin, 
duration of cellular incubation with EVs and concentration of EVs added, as previously 
mentioned. 
Secondly, it is essential to sequence the mRNA of BCR-ABL present in the EVs 
released by drug resistant cells, in order to verify if it is wild-type and/or mutated.  
 Furthermore, it would be interesting to investigate the presence of DNA of BCR-
ABL in those EVs. Indeed, increasing published evidence shows the presence of fragments 
of DNA on the cargo of EVs. In particular, DNA of BCR-ABL was recently found in EVs 
released by K562 cells [158, 159]. Accordingly, it would be interesting to verify the 
packaging of DNA coding for BCR-ABL into the EVs from the cell lines used in this study. 
Moreover, it would be interesting to test if the EVs from the cell lines studied may 
transfer BCR-ABL to BCR-ABL- cells (to other tumor cells but non-leukemic or even to non-
tumor cells). This would be a proof of concept of the intercellular transfer of BCR-ABL and 
would allow studying the functional implications on recipient cells.  
Finally, it would be very interesting to verify if it is possible to detect BCR-ABL in the 
EVs isolated from CML patients’ plasma, as biomarkers of this disease. In fact, circulating 
EVs from liquid biopsies of hematological diseases have been studied with the purpose of 
finding more sensitive and earlier diagnostic and prognostic methods [170]. This would be 
a translational application of the present study, allowing transfer of knowledge into the clinic, 
contributing to early diagnosis and to personalized therapeutic decisions and, thus, possibly 
having impact in CML patients’ survival. 
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Annex 1. Schematic representation of a 96-well plate for determination of the IC50 of the 
imatinib mesylate (STI571). Green and red colors represent the KBM5 and KBM5-STI cell lines, 
respectively. Both cell lines were treated with different STI571 concentrations (columns 2-11, lines 
C-F): 0.04 μM, 0.08 μM, 0.15 μM, 0.31 μM, 0.63 μM, 1.3 μM, 2.5 μM, 5.0 μM, 10 μM and 20 μM. 
Dark green and dark red wells (line G: rows 2, 3 and 6, 7) correspond to the KMB5 and KBM5-STI 
cell lines, respectively, cultured with the higher percentage of DMSO used (equivalent to the one 
used when treating cells with 20 μM of STI571, which is nontoxic, <0.25% per well). Light green and 
light red wells represent the KBM5 and KBM5-STI cells in culture medium only, respectively (line G: 
rows 4, 5 and 8, 9). These 8 wells mentioned (line G from well 2 to well 9) represent a cell proliferation 
control. Yellow wells contained normal culture medium only (Blank). The gray color represents the 
different drug concentrations without the presence of the cells (background). Remaining white wells 
contained PBS or medium to maintain humidity on the plate. 
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Annex 2. General schematic representation of a 96-well plate for the co-culture of recipient 
sensitive cells with EVs released by drug-resistant cells. Green and red colors represent, the 
KBM5 and KBM5-STI cell lines, respectively. Different shades of each green and red colors represent 
the following: Line C (row 2-9): KBM5 cells with addition of PBS; Line D (row 2-11): KBM5 cells with 
addition of 5 μg of EVs derived from KBM5-STI cells; Line E (row 2-11): KBM5 cells with addition of 
5 μg of EVs derived from KBM5 cells. Gray color represents the different drug concentrations without 
the presence of the cells (background). In the two first experiments: 0.1 μM of STI571 was added to 
rows 2 and 3; 12 μM was added to rows 4 and 5; 18 μM (from line B to F) was added to rows 6 and 
7. In the following experiments, the concentrations of STI571 used were 0.2 μM, 3.13 μM or 6.25 
μM. Cells from rows 8 and 9 were cultured with the higher percentage of DMSO used (corresponding 
to the one used when treating cells with 18 μM STI571 or 6.25 μM, which is nontoxic, <0.25% per 
well), as a control. Regarding columns 10 and 11, cells from C and F lines were cultured in normal 
cultured medium during the experiment. Wells from line G did not contain cells. Yellow wells 
contained normal culture medium only, the following wells contained just PBS and medium (line G, 
rows 4 and 5) and the two other wells contained medium, PBS and DMSO at its higher concentration 
in the experiment (line G, rows 6 and 7) – all are Blanks of the experiment. Each condition was 
performed in duplicate. Remaining white wells contained PBS or medium only to maintain humidity 
on the plate. 
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Annex 3. Schematic representation of a 96-well plate for optimization of cell concentration. 
Green and red wells represent the KBM5 and KBM5-STI cell lines, respectively, at different cell 
concentrations (from row 2 to 7: 2.5 x 105 cells/mL; 5 x 105 cells/mL; 8 x 105 cells/mL; 1.5 x 105 
cells/mL; 3 x 105 cells/mL and 6 x105 cells/mL – all the concentrations done in duplicates). Culture 
medium was added to the well represented in yellow (Blank). White wells contained only PBS or 
medium, in order to maintain humidity on the plate.  
 
